PageSourceSearch

https://vyvgarthcp.com/gmg/enroll-patients

html vyvgarthcp.com collected 2026-10-04 04:30:35 UTC 143,262 bytes, 3,499 lines download raw bytes

1
2<!DOCTYPE HTML>
3<html lang="en">
4<head>
5    <meta charset="UTF-8"/>
6    
7
8    
9	
10	<!--Tableau Script should be loaded only on insights at argenx website -->
11    
12    
13    <!-- Japan Font Family Library -->
14    
15    
16    
17        <title>Get Your Patients Started | VYVGART Hytrulo® &amp; VYVGART®</title>
18        <meta name="description" content="Enroll gMG patients for VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) &amp; VYVGART (efgartigimod alfa-fcab). Find program details and support tools."/>
19        
20    
21    
22    	
23    
24    
25        
26    
27    <meta name="template" content="content-page"/>
28    
29    
30    	<meta name="viewport" content="width=device-width, initial-scale=1"/>
31    
32    
33    
34
35    
36    
37
38    <meta name="content-page-ref" content="7wGbLkKsDgux8by4r5N0bE_UEcOhjk52Vitye0lMoL7bsEdAjNwq1IaaMKDW8k_MwMzZQIGup0zt-d163aBMj01WRzkhvuHH-9D1siWbnyo"/>
39<script defer="defer" type="text/javascript" src="/.rum/@adobe/helix-rum-js@%5E2/dist/micro.js"></script>
39
40<link rel="canonical" href="https://vyvgarthcp.com/gmg/enroll-patients"/>
41
42
43
44    
45
46
47
48    
49    
50    
51    <meta property="og:title" content="Get Your Patients Started | VYVGART Hytrulo® &amp; VYVGART®"/>
52
53    <meta name="social-share-title" content="Get Your Patients Started | VYVGART® Hytrulo &amp; VYVGART®"/>
54
55
56
57    <meta property="og:url" content="https://www.vyvgarthcp.com/content/vyvgart/us/en/hcp/gmg/enroll-patients/."/>
58    
59    
60    
61
62    <meta name="social-share-title" content="Get Your Patients Started | VYVGART® Hytrulo &amp; VYVGART®"/>
63
64
65
66    
67    
68    
69    <meta property="og:type" content="website"/>
70
71    <meta name="social-share-title" content="Get Your Patients Started | VYVGART® Hytrulo &amp; VYVGART®"/>
72
73
74
75    
76    
77    
78    <meta property="og:site_name" content="VYVGART"/>
79
80    <meta name="social-share-title" content="Get Your Patients Started | VYVGART® Hytrulo &amp; VYVGART®"/>
81
82
83
84    
85    
86    <meta property="og:image" content="https://www.vyvgarthcp.com/content/vyvgart/us/en/hcp/gmg/enroll-patients.thumb.800.480.png?ck=1779913740419"/>
87    
88
89    <meta name="social-share-title" content="Get Your Patients Started | VYVGART® Hytrulo &amp; VYVGART®"/>
90
91
92
93    
94    
95    
96    <meta property="og:description" content="Enroll gMG patients for VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) &amp; VYVGART (efgartigimod alfa-fcab). Find program details and support tools."/>
97
98    <meta name="social-share-title" content="Get Your Patients Started | VYVGART® Hytrulo &amp; VYVGART®"/>
99
100
101
102
103    
104<meta name="format-detection" content="telephone=no"/>
105
106
107
108
109
110
111
112
113
114
115
116
117
118    <meta name="veevacode" content="34444"/>
119
120
121
122    
123<link rel="stylesheet" href="/etc.clientlibs/argenx/clientlibs/clientlib-argenx-global.lc-e74b47439d06e7c659135265a8a91a61-lc.min.css" type="text/css">
124<link rel="stylesheet" href="/etc.clientlibs/argenx/clientlibs/clientlib-base.lc-431ea75cf562396066b99ae0cf15ec8f-lc.min.css" type="text/css">
125
126
127
128
129
130  
131
132
133
134
135<!-- refer to tickets WCM-1541 and WCM-1046 for the below script -->
136
137<!-- Data Layer -->
138<script>
139    window.dataLayer = window.dataLayer || [];
140
141      window.dataLayer.push({
142      event: "form_engagement",
143      formName: "",
144      formStep:"",
145      eventAction:"",
146      eventLabel:"",
147      Formfieldtype:""
148      });
149</script>
149
150
151    
152    	<!-- Google Tag Manager -->
153    	
153<script>
vendor: 336 bytes, lines 153-157
153(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
154		new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
155		j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
156		' https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
157		})(window,document,'script','dataLayer','
157GTM-KX977PG
vendor: 3 bytes, line 157
157');
157</script>
157
158    	<!-- End Google Tag Manager -->
159    
160     
161
162
163
164    
165    
166    
167
168    
169
170    
171
172
173        
173<script type="text/javascript" src="//assets.adobedtm.com/43e912dd1903/9b76541cf2b6/launch-8b5f11d2b4eb.min.js"></script>
173
174
175
176    
177    
178    
179<link rel="stylesheet" href="/etc.clientlibs/argenx/clientlibs/clientlib-vyvgarthcp.lc-eeddc0a3f092beb256601e26c50eaede-lc.min.css" type="text/css">
180
181
182
183    
184    
185    
186    
187
188
189    
190    
191</head>
192<body class="page basicpage" id="page-c979c2ad2d">
193      
194<!-- Google Tag Manager (noscript) -->
vendor: 82 bytes, lines 194-197
194
195
196    
197        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=
197GTM-KX977PG
vendor: 94 bytes, lines 197-200
197" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
198    
199    
200
201<!-- End Google Tag Manager (noscript) -->
202      
203
204
205
206    
207
208
209
210
211    
212
213
214
215    
216<div class="root container responsivegrid vyvgart-outage--container">
217
218    
219    
220    
221    <div id="container-e51be58c2d" class="cmp-container">
222        
223        <div class="fragment-importer">
224    
225        <div class="xfpage page basicpage">
226
227
228    
229    <div id="container-2b685bed7c" class="cmp-container">
230        
231
232
233<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 ">
234    
235    <div class="container responsivegrid vyvgarthcp-container--header-wrapper aem-GridColumn aem-GridColumn--default--12">
236
237    
238    
239    
240    <div id="container-a32e2d75bd" class="cmp-container">
241        
242        <div class="container responsivegrid vyv-utils--hide-desktop">
243
244    
245    <div id="container-f81bb93d69" class="cmp-container">
246        
247
248
249<div class="aem-Grid aem-Grid--12 aem-Grid--small--12 aem-Grid--default--12 aem-Grid--xsmall--12 ">
250    
251    <div class="teaser-new-rte-v2 teaser vyv-teaser--dropdown -justify-center -border-right__navy aem-GridColumn--small--none aem-GridColumn--small--7 aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--offset--small--0 aem-GridColumn--xsmall--7 aem-GridColumn--default--8 aem-GridColumn--offset--default--0">
252<div id="teaser-new-rte-v2-40a0684339" class="cmp-teaser">
253    
254    
255
256    <div class="cmp-teaser__content">
257        
258    
259
260        
261  <div class="cmp-teaser__title">
262      <a class="cmp-teaser__title-link" href="https://argenx.com/content/dam/argenx-corp/products/vyvgart-hytrulo-prescribing-information.pdf"><p>Prescribing Information</p>
263</a>
264  </div>
265
266        
267    
268
269        
270    
271      
272        <div class="cmp-teaser__action-container">
273            
274    
275      <a class="cmp-teaser__action-link " href="https://argenx.com/content/dam/argenx-corp/products/vyvgart-hytrulo-prescribing-information.pdf" target="_blank">VYVGART Hytrulo</a>
276      
277
278        
279            
280    
281      <a class="cmp-teaser__action-link " href="https://argenx.com/content/dam/argenx-corp/products/vyvgart-prescribing-information.pdf" target="_blank">VYVGART</a>
282      
283
284        
285            
286    
287      <a class="cmp-teaser__action-link " href="https://argenx.com/content/dam/argenx-corp/products/vyvgart-hytrulo-IFU.pdf" target="_blank">PFS Instructions for use</a>
288      
289
290        </div>
291      
292    </div>
293</div>
294
295    
296
297</div>
298<div class="button vyv-button--contact-a-rep aem-GridColumn--small--none aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--xsmall--5 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--offset--small--0 aem-GridColumn--small--5 aem-GridColumn--offset--default--0 aem-GridColumn--default--4">
299<a id="button-ae4972ea72" class="cmp-button" href="#contact-a-rep" target="_self">
300    
301    
302
303    <span class="cmp-button__text">Contact a rep</span> <!--Added context for the button text-->
304</a>
305</div>
306<div class="teaser-new-rte-v2 teaser vyv-teaser--dropdown -theme-navy aem-GridColumn--default--none aem-GridColumn aem-GridColumn--default--12 aem-GridColumn--offset--default--0">
307<div id="teaser-new-rte-v2-2f29771761" class="cmp-teaser">
308    
309    
310
311    <div class="cmp-teaser__content">
312        
313    
314
315        
316  <div class="cmp-teaser__title">
317      <a class="cmp-teaser__title-link" href="#active"><p>SELECT INDICATION: gMG</p>
318</a>
319  </div>
320
321        
322    
323
324        
325    
326      
327        <div class="cmp-teaser__action-container">
328            
329    
330      <a class="cmp-teaser__action-link " href="#active" target="_self">gMG</a>
331      
332
333        
334            
335    
336      <a class="cmp-teaser__action-link " href="/vyvgarthytrulo-cidp" target="_self">CIDP (VYVGART Hytrulo only)</a>
337      
338
339        </div>
340      
341    </div>
342</div>
343
344    
345
346</div>
347
348    
349</div>
350
351    </div>
352
353    
354</div>
355<div class="submenu-header">
356    
357	<div>
358    <header class="cmp-submenu-header cmp-submenu-header-regular">
359        <div class="cmp-submenu-header--mobile">
360            <div class="cmp-submenu-header--top-section-mobile">
361                <div class="cmp-submenu-header--utility-mobile" role="navigation" aria-label="Utility">
362                    
363                        <a class="cmp-submenu-header--utility-item-mobile showInMobileMenu " href="#isi" target="_self">Important Safety Information</a>
364                    
365                    
366                        <a class="cmp-submenu-header--utility-item-mobile  " href="https://www.argenx.com/product/vyvgart-prescribing-information.pdf" target="_blank">Prescribing Information</a>
367                    <div class="cmp-submenu-header--utility-item-mobile  utility-subnavigation-mobile">
368                    
369                        
370                    
371                        
372                    
373                        
374                    
375                </div>
376                    
377                        <a class="cmp-submenu-header--utility-item-mobile showInMobileMenu " href="https://vyvgart.com/" target="_blank">Patient Site</a>
378                    
379                    
380                        <a class="cmp-submenu-header--utility-item-mobile showInMobileMenu " href="/gmg/resources/sign-up" target="_self">Stay Connected</a>
381                    
382                    
383                        <a class="cmp-submenu-header--utility-item-mobile showInMobileMenu search-icon" href="#search" target="_self">Search</a>
384                    
385                    
386                        <a class="cmp-submenu-header--utility-item-mobile  utility-contact-a-rep" href="#contact-a-rep" target="_self">Contact a rep</a>
387                    
388                    
389                    
390                </div>
391            </div>
392            <div class="cmp-submenu-header--header-area-mobile">
393                <div class="cmp-submenu-header--logo-mobile">
394                    <a href="/" target="_self">
395                        <img src="/content/dam/vyvgart/hcp/logos/co-branded-simplified-logo.svg" alt="VYVGART logo"/>
396                        
397                    </a>
398                </div>
399                
400                
401    <div class="cmp-submenu-header__highlight">
402        <div class="cmp-submenu-header__highlight-heading">
403            
404        </div>
405        <div class="cmp-submenu-header__highlight-title">
406            SELECT INDICATION:  gMG
407        </div>
408        <div class="cmp-submenu-header__highlight-eyebrow">
409            VYVGART® (efgartigimod alfa-fcab) for intravenous infusion and VYVGART Hytrulo® (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection are each indicated for the treatment of generalized myasthenia gravis in adult patients who are anti-AChR (acetylcholine receptor) antibody positive.
410        </div>
411        <div>
412    <div id="highlight-sub-menu" class="cmp-submenu-header__highlight-submenu">
413        <div class="cmp-submenu-header__highlight-submenu-items">
414            
415            <a target="_self" href="#active ">
416                <span>gMG</span>
417            </a>
418
419        </div>
420    
421        <div class="cmp-submenu-header__highlight-submenu-items">
422            
423            <a target="_self" href="/vyvgarthytrulo-cidp">
424                <span>CIDP (VYVGART Hytrulo only)</span>
425            </a>
426
427        </div>
428    </div>
429</div>
430    </div>
431
432                <div class="cmp-submenu-header--hamburger-menu-area"> <span class="cmp-submenu-header--hamburger-menu"></span>
433                    <span class="cmp-submenu-header--close-button" style="display: none"></span> <span class="cmp-submenu-header--mobile-before-click"> </span><span class="cmp-submenu-header--mobile-after-click" style="display: none">
434                        </span>
435                </div>
436            </div>
437        </div>
438        
439        <div class="cmp-submenu-header--top-section">
440            <div class="cmp-submenu-header--logo-area">
441                <div class="cmp-submenu-header--logo"><a href="/" target="_self"> <img src="/content/dam/vyvgart/hcp/logos/co-branded-simplified-logo.svg" alt="VYVGART logo"/></a> </div>
442            </div>
443
444            
445    <div class="cmp-submenu-header__highlight">
446        <div class="cmp-submenu-header__highlight-heading">
447            
448        </div>
449        <div class="cmp-submenu-header__highlight-title">
450            SELECT INDICATION:  gMG
451        </div>
452        <div class="cmp-submenu-header__highlight-eyebrow">
453            VYVGART® (efgartigimod alfa-fcab) for intravenous infusion and VYVGART Hytrulo® (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection are each indicated for the treatment of generalized myasthenia gravis in adult patients who are anti-AChR (acetylcholine receptor) antibody positive.
454        </div>
455        <div>
456    <div id="highlight-sub-menu" class="cmp-submenu-header__highlight-submenu">
457        <div class="cmp-submenu-header__highlight-submenu-items">
458            
459            <a target="_self" href="#active ">
460                <span>gMG</span>
461            </a>
462
463        </div>
464    
465        <div class="cmp-submenu-header__highlight-submenu-items">
466            
467            <a target="_self" href="/vyvgarthytrulo-cidp">
468                <span>CIDP (VYVGART Hytrulo only)</span>
469            </a>
470
471        </div>
472    </div>
473</div>
474    </div>
475
476
477            <div class="cmp-submenu-header--utility">
478                <div class="cmp-submenu-header--utility-wrapper" role="navigation" aria-label="Utility">
479                    
480                    
481                        <div class="cmp-submenu-header--utility-item ">
482                            <a href="#isi" target="_self" class="showInMobileMenu  ">Important Safety Information</a>
483                            
484                            
485                            <span class="cmp-submenu-header--utility-divider"> | </span>
486                        </div>
487
488                    
489                        <div class="cmp-submenu-header--utility-item __with-sub">
490                            <a href="https://www.argenx.com/product/vyvgart-prescribing-information.pdf" target="_blank" class="  ">Prescribing Information</a>
491                            <div class="cmp-submenu-header--utility-item-chevron"></div>
492                            <div class="cmp-submenu-header--sub--utility">
493                                
494                                    <a href="https://www.argenx.com/product/vyvgart-hytrulo-prescribing-information.pdf" target="_blank" class="cmp-submenu-header--subItem ">VYVGART Hytrulo</a>
495                                
496                                    <a href="https://www.argenx.com/product/vyvgart-prescribing-information.pdf" target="_blank" class="cmp-submenu-header--subItem ">VYVGART</a>
497                                
498                                    <a href="https://argenx.com/content/dam/argenx-corp/products/vyvgart-hytrulo-IFU.pdf" target="_blank" class="cmp-submenu-header--subItem ">PFS Instructions for use</a>
499                                
500                            </div>
501                            <span class="cmp-submenu-header--utility-divider"> | </span>
502                        </div>
503
504                    
505                        <div class="cmp-submenu-header--utility-item ">
506                            <a href="https://vyvgart.com/" target="_blank" class="showInMobileMenu  ">Patient Site</a>
507                            
508                            
509                            <span class="cmp-submenu-header--utility-divider"> | </span>
510                        </div>
511
512                    
513                        <div class="cmp-submenu-header--utility-item ">
514                            <a href="/gmg/resources/sign-up" target="_self" class="showInMobileMenu  ">Stay Connected</a>
515                            
516                            
517                            <span class="cmp-submenu-header--utility-divider"> | </span>
518                        </div>
519
520                    
521                        <div class="cmp-submenu-header--utility-item ">
522                            <a href="#search" target="_self" class="showInMobileMenu search-icon ">Search</a>
523                            
524                            
525                            <span class="cmp-submenu-header--utility-divider"> | </span>
526                        </div>
527
528                    
529                        <div class="cmp-submenu-header--utility-item ">
530                            <a href="#contact-a-rep" target="_self" class=" utility-contact-a-rep ">Contact a rep</a>
531                            
532                            
533                            <span class="cmp-submenu-header--utility-divider"> | </span>
534                        </div>
535
536                    
537                </div>
538                
539            </div>
540            
541        </div>
542
543        <div class="cmp-submenu-header--main">
544            
545
546            <ul role="navigation" aria-label="Main" class="cmp-submenu-header--main-list cmp-submenu-header--left">
547                
548                    <li class="cmp-submenu-header--mainSectionItem ">
549                        <a href="/gmg" target="_self">
550                            <img class="cmp-submenu-header--main_logo"/>
551                            <span>Home</span>
552                        </a>
553                        <div class=" urlDestination cmp-submenu-header--chevron-expand-no-subItems">
554                        </div>
555                        
556                        <div class="cmp-submenu-header--chevron-collapse-no-subItems" style="display:none"></div>
557                        
558                        
559
560                    </li>
561                
562                    <li class="cmp-submenu-header--mainSectionItem ">
563                        <a href="#" target="_self">
564                            <img class="cmp-submenu-header--main_logo"/>
565                            <span>About</span>
566                        </a>
567                        <div class=" subnavigationMainNav cmp-submenu-header--chevron-expand">
568                        </div>
569                        
570                        <div class="cmp-submenu-header--chevron-collapse" style="display:none"></div>
571                        
572                        <div class="cmp-submenu-header--sub">
573                            
574                                <a href="/gmg/about/gmg" target="_self" class="cmp-submenu-header--subItem">About gMG</a>
575                            
576                                <a href="/gmg/about/moa" target="_self" class="cmp-submenu-header--subItem">Mechanism of action</a>
577                            
578                                <a href="/gmg/about/explore-patient-profiles" target="_self" class="cmp-submenu-header--subItem">Explore patient profiles</a>
579                            
580                        </div>
581
582                    </li>
583                
584                    <li class="cmp-submenu-header--mainSectionItem ">
585                        <a href="/gmg/clinical-data" target="_self">
586                            <img class="cmp-submenu-header--main_logo"/>
587                            <span>Efficacy</span>
588                        </a>
589                        <div class=" urlDestination cmp-submenu-header--chevron-expand-no-subItems">
590                        </div>
591                        
592                        <div class="cmp-submenu-header--chevron-collapse-no-subItems" style="display:none"></div>
593                        
594                        
595
596                    </li>
597                
598                    <li class="cmp-submenu-header--mainSectionItem ">
599                        <a href="/gmg/safety" target="_self">
600                            <img class="cmp-submenu-header--main_logo"/>
601                            <span>Safety</span>
602                        </a>
603                        <div class=" urlDestination cmp-submenu-header--chevron-expand-no-subItems">
604                        </div>
605                        
606                        <div class="cmp-submenu-header--chevron-collapse-no-subItems" style="display:none"></div>
607                        
608                        
609
610                    </li>
611                
612                    <li class="cmp-submenu-header--mainSectionItem ">
613                        <a href="#" target="_self">
614                            <img class="cmp-submenu-header--main_logo"/>
615                            <span>Dosing</span>
616                        </a>
617                        <div class=" subnavigationMainNav cmp-submenu-header--chevron-expand">
618                        </div>
619                        
620                        <div class="cmp-submenu-header--chevron-collapse" style="display:none"></div>
621                        
622                        <div class="cmp-submenu-header--sub">
623                            
624                                <a href="/gmg/dosing/overview" target="_self" class="cmp-submenu-header--subItem">Dosing overview</a>
625                            
626                                <a href="/gmg/dosing/tools" target="_self" class="cmp-submenu-header--subItem">Administration options</a>
627                            
628                        </div>
629
630                    </li>
631                
632                    <li class="cmp-submenu-header--mainSectionItem ">
633                        <a href="#" target="_self">
634                            <img class="cmp-submenu-header--main_logo"/>
635                            <span>Access</span>
636                        </a>
637                        <div class=" subnavigationMainNav cmp-submenu-header--chevron-expand">
638                        </div>
639                        
640                        <div class="cmp-submenu-header--chevron-collapse" style="display:none"></div>
641                        
642                        <div class="cmp-submenu-header--sub">
643                            
644                                <a href="/gmg/access/access-information" target="_self" class="cmp-submenu-header--subItem">Access information</a>
645                            
646                                <a href="/gmg/access/local-coverage-tool" target="_self" class="cmp-submenu-header--subItem">Find local coverage</a>
647                            
648                                <a href="/gmg/access/patient-support-program" target="_self" class="cmp-submenu-header--subItem">Patient support program</a>
649                            
650                        </div>
651
652                    </li>
653                
654                    <li class="cmp-submenu-header--mainSectionItem ">
655                        <a href="/gmg/resources" target="_self">
656                            <img class="cmp-submenu-header--main_logo"/>
657                            <span>Resources</span>
658                        </a>
659                        <div class=" urlDestination cmp-submenu-header--chevron-expand-no-subItems">
660                        </div>
661                        
662                        <div class="cmp-submenu-header--chevron-collapse-no-subItems" style="display:none"></div>
663                        
664                        
665
666                    </li>
667                
668                    <li class="cmp-submenu-header--mainSectionItem ">
669                        <a href="/gmg/enroll-patients" id="submenu-header--enroll-patients-amethyst" target="_self">
670                            <img class="cmp-submenu-header--main_logo"/>
671                            <span>Enroll patients</span>
672                        </a>
673                        <div class=" urlDestination cmp-submenu-header--chevron-expand-no-subItems">
674                        </div>
675                        
676                        <div class="cmp-submenu-header--chevron-collapse-no-subItems" style="display:none"></div>
677                        
678                        
679
680                    </li>
681                
682
683            </ul>
684            <div class="cmp-submenu-header--adaptive-share-wrapper-mobile">
685                
686                
687            </div>
688
689        </div>
690    </header>
691</div>
692
693</div>
694
695        
696    </div>
697
698</div>
699
700    
701</div>
702
703    </div>
704
705    
706</div>
707
708    
709    
710
711
712    
713</div>
714<main class="container responsivegrid">
715
716    
717    
718    
719    <div id="container-71e9ec16d7" class="cmp-container">
720        
721        <div class="container responsivegrid vyvgarthcp-container--fullbleed vyv-theme--co-branded">
722
723    
724    
725    
726    <div id="enroll-patients-hero" class="cmp-container" style="background-image:url(\2f content\2f dam\2fvyvgart\2fhcp\2fgMG_Building_Blocks_Gradient.jpg);background-size:cover;background-repeat:no-repeat;">
727        
728        <div class="container responsivegrid vyvgarthcp-container--content-gutter">
729
730    
731    
732    
733    <div id="container-0d1b55202c" class="cmp-container">
734        
735        <div class="text vyvgarthcp-color--white vyv-spacing--bottom-sm-5 vyvgarthcp-text--font-weight-sm">
736<div id="text-6d309825de" class="cmp-text">
737    <h1 style="	text-align: center;
738">Enroll your adult patients of all gMG serotypes and get them started with <b>VYVGART Hytrulo</b> or <b>VYVGART<sup>1,2*</sup></b></h1>
739
740</div>
741
742    
743
744</div>
745<div class="text vyvgarthcp-color--white vyv-spacing--bottom-sm-8">
746<div id="text-32cda8ed41" class="cmp-text">
747    <p style="	text-align: center;
748"><b>Two ways to enroll patients in My VYVGART<sup>®</sup> Path</b></p>
749
750</div>
751
752    
753
754</div>
755<div class="container responsivegrid">
756
757    
758    <div id="container-bfc3d518c5" class="cmp-container">
759        
760
761
762<div class="aem-Grid aem-Grid--12 aem-Grid--small--12 aem-Grid--default--12 aem-Grid--xsmall--12 ">
763    
764    <div class="teaser-new-rte-v2 teaser vyv-spacing--bottom-sm-6 vyvgarthcp-spacing--desktop-bottom--none vyvgarthcp-button--primary vyvgarthcp-button--rounded-r4 vyv-teaser-image-auto-resize vyv-teaser-image-center-x aem-GridColumn--small--none aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--xsmall--12 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--default--6 aem-GridColumn--offset--default--0">
765<div id="teaser-new-rte-v2-42389e9787" class="cmp-teaser">
766    
767    <div class="cmp-teaser__image">
768<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_257896284/container/container/teaser_new_rte_v2.coreimg{.width}.svg/1779913738993/ep-online-icon.svg" data-asset="/content/dam/vyvgart/hcp/enroll-patients/ep_online-icon.svg" id="image-42389e9787" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject">
769    
770        
771            
772            <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_257896284/container/container/teaser_new_rte_v2.coreimg.svg/1779913738993/ep-online-icon.svg" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/>
773            
774        
775    
776    
777    
778</div>
779
780    
781
782</div>
783
784    <div class="cmp-teaser__content">
785        
786    
787
788        
789  <div class="cmp-teaser__title">
790      <a class="cmp-teaser__title-link" href="https://mypathenroll.com/"><p>Online enrollment</p>
791</a>
792  </div>
793
794        
795    <div class="cmp-teaser__description"><p>Fill out and submit the My VYVGART Path enrollment form online at <b><a href="https://mypathenroll.com/" target="_blank" style="	color: white;
796" rel="noopener noreferrer">MyPathEnroll.com</a></b></p>
797</div>
798
799        
800    
801      
802        <div class="cmp-teaser__action-container">
803            
804    
805      <a class="cmp-teaser__action-link " href="https://mypathenroll.com/" target="_self">Enroll today</a>
806      
807
808        </div>
809      
810    </div>
811</div>
812
813    
814
815</div>
816<div class="teaser-new-rte-v2 teaser vyvgarthcp-button--primary vyvgarthcp-button--rounded-r4 vyv-teaser-image-auto-resize vyv-teaser-image-center-x aem-GridColumn--small--none aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--xsmall--12 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--default--6 aem-GridColumn--offset--default--0">
817<div id="teaser-new-rte-v2-267d399af2" class="cmp-teaser">
818    
819    <div class="cmp-teaser__image">
820<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_257896284/container/container/teaser_new_rte_v2_co.coreimg{.width}.svg/1779913739083/ep-fax-icon.svg" data-asset="/content/dam/vyvgart/hcp/enroll-patients/ep_fax-icon.svg" id="image-267d399af2" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject">
821    
822        
823            
824            <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_257896284/container/container/teaser_new_rte_v2_co.coreimg.svg/1779913739083/ep-fax-icon.svg" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/>
825            
826        
827    
828    
829    
830</div>
831
832    
833
834</div>
835
836    <div class="cmp-teaser__content">
837        
838    
839
840        
841  <div class="cmp-teaser__title">
842      <a class="cmp-teaser__title-link" href="/content/dam/vyvgart/hcp/pdfs/my-vyvgart-path-enrollment-form.pdf"><p>Enrollment via fax</p>
843</a>
844  </div>
845
846        
847    <div class="cmp-teaser__description"><p>Download the enrollment form and fax the completed document to <b>1-833-698-7284</b></p>
848</div>
849
850        
851    
852      
853        <div class="cmp-teaser__action-container">
854            
855    
856      <a class="cmp-teaser__action-link " href="/content/dam/vyvgart/hcp/pdfs/my-vyvgart-path-enrollment-form.pdf.html" target="_self">Download form</a>
857      
858
859        </div>
860      
861    </div>
862</div>
863
864    
865
866</div>
867
868    
869</div>
870
871    </div>
872
873    
874</div>
875<div class="text vyvgarthcp-text--small vyv-spacing--top-sm-8 vyv-spacing--top-sm-5">
876<div id="text-b493d2d1f7" class="cmp-text">
877    <p class="vyvgarthcp-text--footnote">*&#34;All gMG serotypes&#34; refers to anti–AChR-Ab positive, anti–MuSK-Ab positive, anti–LRP4-Ab positive, or triple seronegative.<sup>1,2 </sup><br />
878Triple seronegative&#61;anti-AChR, anti-MuSK, and anti-LRP4 antibodies negative.<sup>1,2<br />
879 </sup>AChR-Ab&#61;acetylcholine receptor antibody; gMG&#61;generalized myasthenia gravis; LRP4-Ab&#61;low-density lipoprotein receptor-related protein 4 antibody; MuSK-Ab&#61;muscle-specific tyrosine 
 kinase antibody.</p>
880
881</div>
882
883    
884
885</div>
886
887        
888    </div>
889
890</div>
891
892        
893    </div>
894
895</div>
896<div class="container responsivegrid vyvgarthcp-container--section-gutter">
897
898    
899    
900    
901    <div id="key-details" class="cmp-container">
902        
903        <div class="text vyvgarthcp-color--primary vyv-spacing--bottom-sm-10">
904<div id="text-44e8ed7f3c" class="cmp-text">
905    <h2 style="	text-align: center;
906">Key details about the enrollment process</h2>
907
908</div>
909
910    
911
912</div>
913<div class="container responsivegrid vyvgarthcp-container--group flex _items-stretch reset-flex--mobile vyv-spacing--bottom-sm-10">
914
915    
916    <div id="container-a589892a08" class="cmp-container">
917        
918
919
920<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 aem-Grid--xsmall--12 ">
921    
922    <div class="teaser-new-rte-v2 teaser vyvgarthcp-teaser-rte--card vyv-spacing--bottom-sm-6 vyvgarthcp-spacing--desktop-bottom--none __cta-anchor--bottom vyv-teaser--rounded-3 vyv-teaser-theme--aqua-to-lt-purple vyv-teaser--padding-lg aem-GridColumn--offset--xsmall--0 aem-GridColumn--xsmall--12 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--default--12">
923<div id="teaser-new-rte-v2-ce11f70ad0" class="cmp-teaser">
924    
925    
926
927    <div class="cmp-teaser__content">
928        
929    
930
931        
932  <div class="cmp-teaser__title">
933      <a class="cmp-teaser__title-link" href="/gmg/access/patient-support-program"><h3>My VYVGART Path</h3>
934</a>
935  </div>
936
937        
938    <div class="cmp-teaser__description"><p>Learn more about how our comprehensive patient support program can help you and your patients.</p>
939</div>
940
941        
942    
943      
944        <div class="cmp-teaser__action-container">
945            
946    
947      <a class="cmp-teaser__action-link " href="/gmg/access/patient-support-program" target="_self">Get the details</a>
948      
949
950        </div>
951      
952    </div>
953</div>
954
955    
956
957</div>
958<div class="teaser-new-rte-v2 teaser vyvgarthcp-teaser-rte--card vyv-spacing--bottom-sm-6 vyvgarthcp-spacing--desktop-bottom--none __cta-anchor--bottom vyv-teaser--rounded-3 vyv-teaser-theme--aqua-to-lt-purple vyv-teaser--padding-lg aem-GridColumn--offset--xsmall--0 aem-GridColumn--xsmall--12 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--default--12">
959<div id="teaser-new-rte-v2-37d07050d0" class="cmp-teaser">
960    
961    
962
963    <div class="cmp-teaser__content">
964        
965    
966
967        
968  <div class="cmp-teaser__title">
969      <a class="cmp-teaser__title-link" href="/content/dam/vyvgart/hcp/pdfs/gMG-VYVGART-and-VYVGART-Hytrulo-Billing-and-Coding-Guide.pdf"><h3>Billing &amp; coding</h3>
970</a>
971  </div>
972
973        
974    <div class="cmp-teaser__description"><p>For <b>VYVGART Hytrulo</b>, use HCPCS J-Code <b>J9334</b> (injection, efgartigimod alfa 2 mg and hyaluronidase-qvfc). For <b>VYVGART</b>, use HCPCS J-Code <b>J9332</b> (injection, efgartigimod alfa-fcab 2 mg). <b>Do not use</b> J9332 for VYVGART Hytrulo.</p>
975<p> </p>
976<p> </p>
977</div>
978
979        
980    
981      
982        <div class="cmp-teaser__action-container">
983            
984    
985      <a class="cmp-teaser__action-link " href="/content/dam/vyvgart/hcp/pdfs/gMG-VYVGART-and-VYVGART-Hytrulo-Billing-and-Coding-Guide.pdf.html" target="_self">Download the Billing and Coding Guide for VYVGART Hytrulo or VYVGART for IV infusion</a>
986      
987
988        </div>
989      
990    </div>
991</div>
992
993    
994
995</div>
996<div class="teaser-new-rte-v2 teaser vyvgarthcp-teaser-rte--card __cta-anchor--bottom vyv-teaser--rounded-3 vyv-teaser-theme--aqua-to-lt-purple vyv-teaser--padding-lg aem-GridColumn--offset--xsmall--0 aem-GridColumn--xsmall--12 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--default--12">
997<div id="teaser-new-rte-v2-d860774939" class="cmp-teaser">
998    
999    
1000
1001    <div class="cmp-teaser__content">
1002        
1003    
1004
1005        
1006  <div class="cmp-teaser__title">
1007      <a class="cmp-teaser__title-link" href="/gmg/access/access-information#co-pay"><h3>VYVGART Co-pay Program</h3>
1008</a>
1009  </div>
1010
1011        
1012    <div class="cmp-teaser__description"><p>Your patients could be eligible to save on their treatment with <b>VYVGART Hytrulo</b> or <b>VYVGART</b>.</p>
1013</div>
1014
1015        
1016    
1017      
1018        <div class="cmp-teaser__action-container">
1019            
1020    
1021      <a class="cmp-teaser__action-link " href="/gmg/access/access-information#co-pay" target="_self">Find savings</a>
1022      
1023
1024        </div>
1025      
1026    </div>
1027</div>
1028
1029    
1030
1031</div>
1032
1033    
1034</div>
1035
1036    </div>
1037
1038    
1039</div>
1040<div class="text vyvgarthcp-text--small vyv-spacing--top-sm-3">
1041<div id="text-66723421fe" class="cmp-text">
1042    <p style="	text-align: center;
1043">HCPCS&#61;Healthcare Common Procedure Coding System.</p>
1044
1045</div>
1046
1047    
1048
1049</div>
1050
1051        
1052    </div>
1053
1054</div>
1055<div class="container responsivegrid vyvgarthcp-container--fullbleed -padding-sm-9">
1056
1057    
1058    
1059    
1060    <div id="container-798e24a725" class="cmp-container" style="background-color:#E7F6F5;">
1061        
1062        <div class="container responsivegrid vyvgarthcp-container--content-gutter flex _items-center reset-flex--mobile">
1063
1064    
1065    <div id="container-f860a3cf1e" class="cmp-container">
1066        
1067
1068
1069<div class="aem-Grid aem-Grid--12 aem-Grid--small--12 aem-Grid--default--12 aem-Grid--xsmall--12 ">
1070    
1071    <div class="text vyvgarthcp-color--primary vyv-spacing--bottom-sm-5 vyvgarthcp-spacing--desktop-bottom--none vyvgarthcp-text--center-mobile aem-GridColumn--small--none aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--xsmall--12 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--default--5 aem-GridColumn--offset--default--0">
1072<div id="text-268c01df46" class="cmp-text">
1073    <h3>Need support?</h3>
1074
1075</div>
1076
1077    
1078
1079</div>
1080<div class="text vyvgarthcp-color--primary vyvgarthcp-text--center-mobile vyvgarthcp-text--wrap-pretty aem-GridColumn--small--none aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--xsmall--12 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--default--6 aem-GridColumn--offset--default--1">
1081<div id="text-5080460aa1" class="cmp-text">
1082    <p>Contact My VYVGART Path at <b>1-833-697-2841</b> for assistance for your patients who are on <b>VYVGART Hytrulo</b> or <b>VYVGART</b>.</p>
1083
1084</div>
1085
1086    
1087
1088</div>
1089
1090    
1091</div>
1092
1093    </div>
1094
1095    
1096</div>
1097
1098        
1099    </div>
1100
1101</div>
1102<div class="container responsivegrid vyvgarthcp-container--fullbleed vyv-theme--deep-nav
1102y-gradient">
1103
1104    
1105    
1106    
1107    <div id="container-239119cbcd" class="cmp-container">
1108        
1109        <div class="container responsivegrid vyvgarthcp-container--content-gutter">
1110
1111    
1112    
1113    
1114    <div id="container-6b5b41936a" class="cmp-container">
1115        
1116        <div class="text vyvgarthcp-color--white vyv-spacing--bottom-sm-8">
1117<div id="text-b011274fb0" class="cmp-text">
1118    <h2>Considerations for starting and staying on treatment</h2>
1119
1120</div>
1121
1122    
1123
1124</div>
1125<div class="teaser-new-rte teaser vyvgarthcp-spacing--bottom-medium vyvgarthcp-teaser-rte--theme-white vyv-teaser-layout--horizontal vyv-teaser-layout--vertical-mobile vyv-teaser-image-auto-resize vyv-teaser-image-center-x vyvgarthcp-teaser--desc-textalign-center-mobile">
1126<div id="teaser-new-rte-bc2cc80d41" class="cmp-teaser">
1127    
1128    <div class="cmp-teaser__image">
1129<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy.coreimg{.width}.svg/1779913739660/ep-checkmark-icon.svg" data-asset="/content/dam/vyvgart/hcp/enroll-patients/ep_checkmark-icon.svg" id="image-bc2cc80d41" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject">
1130    
1131        
1132            
1133            <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy.coreimg.svg/1779913739660/ep-checkmark-icon.svg" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/>
1134            
1135        
1136    
1137    
1138    
1139</div>
1140
1141    
1142
1143</div>
1144
1145    <div class="cmp-teaser__content">
1146        
1147    
1148
1149        
1150    <h2 class="cmp-teaser__title">
1151        <p><b>MG-ADL assessments</b></p>
1152
1153    </h2>
1154
1155        
1156    <div class="cmp-teaser__description"><p>Share the MG-ADL scale and partner with patients to establish their baseline total score at the start of therapy, then track changes over time to supp
1156ort ongoing treatment management</p>
1157</div>
1158
1159        
1160    
1161      
1162        
1163      
1164    </div>
1165</div>
1166
1167    
1168
1169</div>
1170<div class="teaser-new-rte teaser vyvgarthcp-spacing--bottom-medium vyvgarthcp-teaser-rte--theme-white vyv-teaser-layout--horizontal vyv-teaser-layout--vertical-mobile vyv-teaser-image-auto-resize vyv-teaser-image-center-x vyvgarthcp-teaser--desc-textalign-center-mobile">
1171<div id="teaser-new-rte-98826b2f1a" class="cmp-teaser">
1172    
1173    <div class="cmp-teaser__image">
1174<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy_.coreimg{.width}.svg/1779913739676/ep-chat-icon.svg" data-asset="/content/dam/vyvgart/hcp/enroll-patients/ep_chat-icon.svg" id="image-98826b2f1a" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject">
1175    
1176        
1177            
1178            <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy_.coreimg.svg/1779913739676/ep-chat-icon.svg" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/>
1179            
1180        
1181    
1182    
1183    
1184</div>
1185
1186    
1187
1188</div>
1189
1190    <div class="cmp-teaser__content">
1191        
1192    
1193
1194        
1195    <h2 class="cmp-teaser__title">
1196        <p><b>Patient counseling information</b></p>
1197
1198    </h2>
1199
1200        
1201    <div class="cmp-teaser__description"><p>Discuss the risks of infections, hypersensitivity reactions, and infusion- or injection-related reactions associated with initiating therapy and ongoing treatment*</p>
1202</div>
1203
1204        
1205    
1206      
1207        
1208      
1209    </div>
1210</div>
1211
1212    
1213
1214</div>
1215<div class="teaser-new-rte teaser vyvgarthcp-spacing--bottom-medium vyvgarthcp-teaser-rte--theme-white vyv-teaser-layout--horizontal vyv-teaser-layout--vertical-mobile vyv-teaser-image-auto-resize vyv-teaser-image-center-x vyvgarthcp-teaser--desc-textalign-center-mobile">
1216<div id="teaser-new-rte-494886ee59" class="cmp-teaser">
1217    
1218    <div class="cmp-teaser__image">
1219<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy__1519434799.coreimg{.width}.svg/1779913739696/ep-medical-icon.svg" data-asset="/content/dam/vyvgart/hcp/enroll-patients/ep_medical-icon.svg" id="image-494886ee59" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject">
1220    
1221        
1222            
1223            <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy__1519434799.coreimg.svg/1779913739696/ep-medical-icon.svg" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/>
1224            
1225        
1226    
1227    
1228    
1229</div>
1230
1231    
1232
1233</div>
1234
1235    <div class="cmp-teaser__content">
1236        
1237    
1238
1239        
1240    <h2 class="cmp-teaser__title">
1241        <p><b>Sites of care</b></p>
1242
1243    </h2>
1244
1245        
1246    <div class="cmp-teaser__description"><p>Review options for administration to understand patient needs and preferences</p>
1247</div>
1248
1249        
1250    
1251      
1252        
1253      
1254    </div>
1255</div>
1256
1257    
1258
1259</div>
1260<div class="teaser-new-rte-v2 teaser vyv-spacing--bottom-sm-8 vyv-teaser-layout--horizontal vyv-teaser-layout--vertical-mobile vyv-teaser-image-auto-resize vyv-teaser-image-center-x vyv-teaser-text-center-x-mobile">
1261<div id="teaser-new-rte-v2-269371e240" class="cmp-teaser">
1262    
1263    <div class="cmp-teaser__image">
1264<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_v2.coreimg{.width}.svg/1779913739711/ep-calendar-icon.svg" data-asset="/content/dam/vyvgart/hcp/enroll-patients/ep_calendar-icon.svg" id="image-269371e240" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject">
1265    
1266        
1267            
1268            <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_v2.coreimg.svg/1779913739711/ep-calendar-icon.svg" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/>
1269            
1270        
1271    
1272    
1273    
1274</div>
1275
1276    
1277
1278</div>
1279
1280    <div class="cmp-teaser__content">
1281        
1282    
1283
1284        
1285  <div class="cmp-teaser__title">
1286      <p><b>Access to multiple treatment cycles</b></p>
1287
1288  </div>
1289
1290        
1291    <div class="cmp-teaser__description"><p>Initial authorization may allow for multiple treatment cycles for the majority of patients</p>
1292</div>
1293
1294        
1295    
1296      
1297        
1298      
1299    </div>
1300</div>
1301
1302    
1303
1304</div>
1305<div class="teaser-new-rte teaser vyvgarthcp-spacing--bottom-medium vyvgarthcp-teaser
1305-rte--theme-white vyv-teaser-layout--horizontal vyv-teaser-layout--vertical-mobile vyv-teaser-image-auto-resize vyv-teaser-image-center-x vyvgarthcp-teaser--desc-textalign-center-mobile">
1306<div id="teaser-new-rte-e8a6c7d368" class="cmp-teaser">
1307    
1308    <div class="cmp-teaser__image">
1309<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy__1576980065.coreimg{.width}.svg/1779913739726/ep-syringe-icon.svg" data-asset="/content/dam/vyvgart/hcp/enroll-patients/ep_syringe-icon.svg" id="image-e8a6c7d368" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject">
1310    
1311        
1312            
1313            <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy__1576980065.coreimg.svg/1779913739726/ep-syringe-icon.svg" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/>
1314            
1315        
1316    
1317    
1318    
1319</div>
1320
1321    
1322
1323</div>
1324
1325    <div class="cmp-teaser__content">
1326        
1327    
1328
1329        
1330    <h2 class="cmp-teaser__title">
1331        <p><b>No treatment-specific vaccinations are required for treatment</b><sup><b>1,2</b></sup></p>
1332
1333    </h2>
1334
1335        
1336    <div class="cmp-teaser__description"><p>Evaluate the need for age-appropriate vaccines according to immunization guidelines before start of a treatment cycle with <span class="vyvgarthcp-color--aqua"><b>VYVGART<sup>†</sup></b></span></p>
1337</div>
1338
1339        
1340    
1341      
1342        
1343      
1344    </div>
1345</div>
1346
1347    
1348
1349</div>
1350<div class="teaser-new-rte teaser vyvgarthcp-spacing--bottom-medium vyvgarthcp-teaser-rte--theme-white vyv-teaser-layout--horizontal vyv-teaser-layout--vertical-mobile vyv-teaser-image-auto-resize vyv-teaser-image-center-x vyvgarthcp-teaser--desc-textalign-center-mobile">
1351<div id="teaser-new-rte-757112aff9" class="cmp-teaser">
1352    
1353    <div class="cmp-teaser__image">
1354<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy__1135262305.coreimg{.width}.svg/1779913739742/ep-certification-icon.svg" data-asset="/content/dam/vyvgart/hcp/enroll-patients/ep_certification-icon.svg" id="image-757112aff9" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject">
1355    
1356        
1357            
1358            <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy__1135262305.coreimg.svg/1779913739742/ep-certification-icon.svg" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/>
1359            
1360        
1361    
1362    
1363    
1364</div>
1365
1366    
1367
1368</div>
1369
1370    <div class="cmp-teaser__content">
1371        
1372    
1373
1374        
1375    <h2 class="cmp-teaser__title">
1376        <p><b>No REMS required</b></p>
1377
1378    </h2>
1379
1380        
1381    <div class="cmp-teaser__description"><p><b class="vyvgarthcp-color--aqua">VYVGART</b> does not require any specific training or certification prior to starting treatment at this time</p>
1382</div>
1383
1384        
1385    
1386      
1387        
1388      
1389    </div>
1390</div>
1391
1392    
1393
1394</div>
1395<div class="teaser-new-rte teaser vyvgarthcp-spacing--bottom-medium vyvgarthcp-teaser-rte--theme-white vyv-teaser-layout--horizontal vyv-teaser-layout--vertical-mobile vyv-teaser-image-auto-resize vyv-teaser-image-center-x vyvgarthcp-teaser--desc-textalign-center-mobile">
1396<div id="teaser-new-rte-791f5b5621" class="cmp-teaser">
1397    
1398    <div class="cmp-teaser__image">
1399<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy__544052684.coreimg{.width}.svg/1779913739757/ep-no-routine-icon.svg" data-asset="/content/dam/vyvgart/hcp/enroll-patients/ep_no_routine-icon.svg" id="image-791f5b5621" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject">
1400    
1401        
1402            
1403            <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy__544052684.coreimg.svg/1779913739757/ep-no-routine-icon.svg" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/>
1404            
1405        
1406    
1407    
1408    
1409</div>
1410
1411    
1412
1413</div>
1414
1415    <div class="cmp-teaser__content">
1416        
1417    
1418
1419        
1420    <h2 class="cmp-teaser__title">
1421        <p><b>No routine lab monitoring required</b></p>
1422
1423    </h2>
1424
1425        
1426    <div class="cmp-teaser__description"><p>There are no routine lab monitoring requirements for patients during treatment with <b class="vyvgarthcp-color--aqua">VYVGART</b>. Continue to evaluate response and monitor patients for possible side effects<sup>‡</sup></p>
1427</div>
1428
1429        
1430    
1431      
1432        
1433      
1434    </div>
1435</div>
1436
1437    
1438
1439</div>
1440<div class="teaser-new-rte teaser vyvgarthcp-spacing--bottom-small vyvgarthcp-teaser
1440-rte--theme-white vyv-teaser-layout--horizontal vyv-teaser-layout--vertical-mobile vyv-teaser-image-auto-resize vyv-teaser-image-center-x vyvgarthcp-teaser--desc-textalign-center-mobile">
1441<div id="teaser-new-rte-4c41f9c7c5" class="cmp-teaser">
1442    
1443    <div class="cmp-teaser__image">
1444<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy__1233999702.coreimg{.width}.svg/1779913739772/ep-warning-icon.svg" data-asset="/content/dam/vyvgart/hcp/enroll-patients/ep_warning-icon.svg" id="image-4c41f9c7c5" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject">
1445    
1446        
1447            
1448            <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1868349668/container/teaser_new_rte_copy__1233999702.coreimg.svg/1779913739772/ep-warning-icon.svg" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/>
1449            
1450        
1451    
1452    
1453    
1454</div>
1455
1456    
1457
1458</div>
1459
1460    <div class="cmp-teaser__content">
1461        
1462    
1463
1464        
1465    <h2 class="cmp-teaser__title">
1466        <p><b>No Boxed Warning</b></p>
1467
1468    </h2>
1469
1470        
1471    <div class="cmp-teaser__description"><p>Please see the full Prescribing Information for <b class="vyvgarthcp-color--lavender-fields">VYVGART Hytrulo</b> and <b class="vyvgarthcp-color--aqua">VYVGART</b> before starting patients on treatment</p>
1472</div>
1473
1474        
1475    
1476      
1477        
1478      
1479    </div>
1480</div>
1481
1482    
1483
1484</div>
1485<div class="text vyvgarthcp-color--white">
1486<div id="text-9952bc1b38" class="cmp-text">
1487    <p class="vyvgarthcp-text--footnote">*Please also see the Patient Counseling Information in Section 17 of the Prescribing Information.</p>
1488<p class="vyvgarthcp-text--footnote"><sup>†</sup>In accordance with the recommendations found in Section 2.1 of the Prescribing Information.
</p>
1489<p class="vyvgarthcp-text--footnote"><sup>‡</sup>Patients in the ADAPT-SC and ADAPT clinical trials were required to have IgG levels of at least 6 g/L at study entry. Please also see the Warnings and Precautions found in Section 5 of the Prescribing Information.<sup>1,2</sup></p>
1490<p class="vyvgarthcp-text--footnote">VYVGART refers collectively to VYVGART Hytrulo for subcutaneous injection and VYVGART for intravenous infusion.<sup>1,2 </sup><br />
1491</p>
1492<p class="vyvgarthcp-text--footnote">IgG&#61;immunoglobulin G; MG-ADL&#61;Myasthenia Gravis Activities of Daily Living; REMS&#61;Risk Evaluation and Mitigation Strategy.</p>
1493
1494</div>
1495
1496    
1497
1498</div>
1499
1500        
1501    </div>
1502
1503</div>
1504
1505        
1506    </div>
1507
1508</div>
1509<div class="container responsivegrid">
1510
1511    
1512    
1513    
1514    <div id="enrollment-support" class="cmp-container">
1515        
1516        <div class="container responsivegrid vyvgarthcp-container--section-gutter">
1517
1518    
1519    
1520    
1521    <div id="enroll-ico-section" class="cmp-container">
1522        
1523        <div class="container responsivegrid vyv-spacing--bottom-sm-9">
1524
1525    
1526    
1527    
1528    <div id="container-8a26dc0b9f" class="cmp-container">
1529        
1530        <div class="text vyv-spacing--bottom-sm-3 vyv-spacing--bottom-sm-4">
1531<div id="text-d9b6308b1b" class="cmp-text">
1532    <h2 style="	text-align: center;
1533">Enrollment support for you and your practice</h2>
1534
1535</div>
1536
1537    
1538
1539</div>
1540
1541        
1542    </div>
1543
1544</div>
1545<div class="container responsivegrid">
1546
1547    
1548    <div id="container-902294d04c" class="cmp-container">
1549        
1550
1551
1552<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 ">
1553    
1554    <div class="container responsivegrid vyvgarthcp-container--group vyv-spacing--bottom-sm-8 aem-GridColumn aem-GridColumn--default--12">
1555
1556    
1557    <div id="container-8d9f3dc078" class="cmp-container">
1558        
1559
1560
1561<div class="aem-Grid aem-Grid--12 aem-Grid--small--12 aem-Grid--default--12 aem-Grid--xsmall--12 ">
1562    
1563    <div class="teaser-new-rte teaser vyvgarthcp-teaser-rte--card vyvgarthcp-spacing--bottom-small vyvgarthcp-spacing--desktop-bottom--none vyvgarthcp-teaser-rte--theme-primary __vertical-center-mobile aem-GridColumn--small--none aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--xsmall--12 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--default--6 aem-GridColumn--offset--default--0">
1564<div id="teaser-new-rte-5b30045373" class="cmp-teaser">
1565    
1566    <div class="cmp-teaser__image">
1567<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1828189094/container/container/container_1634477729_1018510281/teaser_new_rte_copy_.coreimg.90{.width}.png/1779913739906/enrollment-form.png" data-cmp-widths="768,1200,1440,1980" data-asset="/content/dam/vyvgart/hcp/resources/video-library-thumbn
1567ails/enrollment-form.png" id="image-5b30045373" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject">
1568    <a class="cmp-image__link" href="/content/dam/vyvgart/hcp/pdfs/my-vyvgart-path-enrollment-form.pdf" data-cmp-hook-image="link">
1569        <noscript data-cmp-hook-image="noscript">
1570            
1571            <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1828189094/container/container/container_1634477729_1018510281/teaser_new_rte_copy_.coreimg.png/1779913739906/enrollment-form.png" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/>
1572            
1573        </noscript>
1574    </a>
1575    
1576    
1577</div>
1578
1579    
1580
1581</div>
1582
1583    <div class="cmp-teaser__content">
1584        
1585    
1586
1587        
1588    <h2 class="cmp-teaser__title">
1589        <a class="cmp-teaser__title-link" href="/content/dam/vyvgart/hcp/pdfs/my-vyvgart-path-enrollment-form.pdf"><p><b>Enrollment Form</b></p>
1590</a>
1591    </h2>
1592
1593        
1594    <div class="cmp-teaser__description"><p>Downloadable version of the VYVGART Hytrulo and VYVGART enrollment form to fill out and fax to get patients started on treatment and enrolled in My VYVGART Path.</p>
1595</div>
1596
1597        
1598    
1599      
1600        
1601      
1602    </div>
1603</div>
1604
1605    
1606
1607</div>
1608<div class="teaser-new-rte teaser vyvgarthcp-teaser-rte--card vyvgarthcp-teaser-rte--theme-primary __vertical-center-mobile aem-GridColumn--small--none aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--xsmall--12 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--default--6 aem-GridColumn--offset--default--0">
1609<div id="teaser-new-rte-6b6ca9393c" class="cmp-teaser">
1610    
1611    <div class="cmp-teaser__image">
1612<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1828189094/container/container/container_1634477729_1018510281/teaser_new_rte_copy__8698319.coreimg.90{.width}.jpeg/1779913739974/spanish-enrollment-form-thumb.jpeg" data-cmp-widths="768,1200,1440,1980" data-asset="/content/dam/vyvgart/hcp/resources/video-library-thumbnails/spanish-enrollment-form-thumb.jpg" id="image-6b6ca9393c" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject">
1613    <a class="cmp-image__link" href="/content/dam/vyvgart/hcp/pdfs/PSP_Enrollment_Form_Spanish_PDF.pdf" data-cmp-hook-image="link">
1614        <noscript data-cmp-hook-image="noscript">
1615            
1616            <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1828189094/container/container/container_1634477729_1018510281/teaser_new_rte_copy__8698319.coreimg.jpeg/1779913739974/spanish-enrollment-form-thumb.jpeg" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/>
1617            
1618        </noscript>
1619    </a>
1620    
1621    
1622</div>
1623
1624    
1625
1626</div>
1627
1628    <div class="cmp-teaser__content">
1629        
1630    
1631
1632        
1633    <h2 class="cmp-teaser__title">
1634        <a class="cmp-teaser__title-link" href="/content/dam/vyvgart/hcp/pdfs/PSP_Enrollment_Form_Spanish_PDF.pdf"><p><b>Spanish Enrollment Form</b></p>
1635</a>
1636    </h2>
1637
1638        
1639    <div class="cmp-teaser__description"><p>Downloadable Spanish-language version of the VYVGART Hytrulo and VYVGART enrollment form to fill out and fax to get patients started on treatment and enrolled in My VYVGART Path.</p>
1640</div>
1641
1642        
1643    
1644      
1645        
1646      
1647    </div>
1648</div>
1649
1650    
1651
1652</div>
1653
1654    
1655</div>
1656
1657    </div>
1658
1659    
1660</div>
1661<div class="container responsivegrid vyvgarthcp-container--group container--reset-padding aem-GridColumn aem-GridColumn--default--12">
1662
1663    
1664    <div id="container-2fd8a9c410" class="cmp-container">
1665        
1666
1667
1668<div class="aem-Grid aem-Grid--12 aem-Grid--small--12 aem-Grid--default--12 aem-Grid--xsmall--12 ">
1669    
1670    <div class="teaser-new-rte teaser vyvgarthcp-teaser-rte--card __title-color-deep-navy vyvgarthcp-spacing--bottom-small vyvgarthcp-spacing--desktop-bottom--none vyvgarthcp-teaser-rte--theme-primary __vertical-center-mobile aem-GridColumn--small--none aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--xsmall--12 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--default--6 aem-GridColumn--offset--default--0">
1671<div id="teaser-new-rte-42fbad296a" class="cmp-teaser">
1672    
1673    <div class="cmp-teaser__image">
1674<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1828189094/container/container/container_1634477729_758183788/teaser_new_rte_copy_.coreimg.90{.width}.png/1779913740066/ep-hcp-my-vyvgart-path-overview-brochure-thumb.png" data-cmp-widths="768,1200,1440,1980" data-asset="/content/dam/vyvgart/hcp/enroll-patients/ep-hcp-my-vyvgart-path-overview-brochure-thumb.png" id="image-42fbad296a" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject">
1675    <a class="cmp-image__link" href="/content/dam/vyvgart/hcp/pdfs/SC-Update-PSP-Program-Overview-Brochure-HCP.pdf" data-cmp-hook-image="link">
1676        <noscript data-cmp-hook-image="noscript">
1677            
1678            <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1828189094/container/container/container_1634477729_758183788/teaser_new_rte_copy_.coreimg.png/1779913740066/ep-hcp-my-vyvgart-path-overview-brochure-thumb.png" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/>
1679            
1680        </noscript>
1681    </a>
1682    
1683    
1684</div>
1685
1686    
1687
1688</div>
1689
1690    <div class="cmp-teaser__content">
1691        
1692    
1693
1694        
1695    <h2 class="cmp-teaser__title">
1696        <a class="cmp-teaser__title-link" href="/content/dam/vyvgart/hcp/pdfs/SC-Update-PSP-Program-Overview-Brochure-HCP.pdf"><p><b>My VYVGART Path HCP Overview Brochure</b></p>
1697</a>
1698    </h2>
1699
1700        
1701    <div class="cmp-teaser__description"><p>An overview of support offerings for you and your patients through the My VYVGART Path program.</p>
1702</div>
1703
1704        
1705    
1706      
1707        
1708      
1709    </div>
1710</div>
1711
1712    
1713
1714</div>
1715<div class="teaser-new-rte teaser vyvgarthcp-teaser-rte--card vyvgarthcp-teaser-rte--theme-primary __vertical-center-mobile aem-GridColumn--small--none aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--xsmall--12 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--default--6 aem-GridColumn--offset--default--0">
1716<div id="teaser-new-rte-502be11c1c" class="cmp-teaser">
1717    
1718    <div class="cmp-teaser__image">
1719<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1828189094/container/container/container_1634477729_758183788/teaser_new_rte_copy__8698319.coreimg.90{.width}.png/1779913740140/ep-prefilled-syringe-faqs-thumb.png" data-cmp-widths="768,1200,1440,1980" data-asset="/content/dam/vyvgart/hcp/enroll-patients/ep-prefilled-syringe-faqs-thumb.png" id="image-502be11c1c" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject">
1720    <a class="cmp-image__link" href="/content/dam/vyvgart/hcp/pdfs/VYVGART-Hytrulo-Prefilled-Syringe-FAQs.pdf" data-cmp-hook-image="link">
1721        <noscript data-cmp-hook-image="noscript">
1722            
1723            <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients/_jcr_content/root/container/container_1828189094/container/container/container_1634477729_758183788/teaser_new_rte_copy__8698319.coreimg.png/1779913740140/ep-prefilled-syringe-faqs-thumb.png" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt/>
1724            
1725        </noscript>
1726    </a>
1727    
1728    
1729</div>
1730
1731    
1732
1733</div>
1734
1735    <div class="cmp-teaser__content">
1736        
1737    
1738
1739        
1740    <h2 class="cmp-teaser__title">
1741        <a class="cmp-teaser__title-link" href="/content/dam/vyvgart/hcp/pdfs/VYVGART-Hytrulo-Prefilled-Syringe-FAQs.pdf"><p><b>Prefilled Syringe FAQs</b></p>
1742</a>
1743    </h2>
1744
1745        
1746    <div class="cmp-teaser__description"><p>A comprehensive downloadable resource addressing a wide range of frequently asked questions about the VYVGART Hytrulo single-dose prefilled syringe.</p>
1747</div>
1748
1749        
1750    
1751      
1752        
1753      
1754    </div>
1755</div>
1756
1757    
1758
1759</div>
1760
1761    
1762</div>
1763
1764    </div>
1765
1766    
1767</div>
1768
1769    
1770</div>
1771
1772    </div>
1773
1774    
1775</div>
1776<div class="container responsivegrid vyv-spacing--top-md-3">
1777
1778    
1779    
1780    
1781    <div id="container-0e6ac4cfbb" class="cmp-container">
1782        
1783        <div class="text vyvgarthcp-text--small">
1784<div id="text-421fcbfdee" class="cmp-text">
1785    <p>HCP&#61;healthcare professional.</p>
1786
1787</div>
1788
1789    
1790
1791</div>
1792
1793        
1794    </div>
1795
1796</div>
1797
1798        
1799    </div>
1800
1801</div>
1802
1803        
1804    </div>
1805
1806</div>
1807<div class="container responsivegrid">
1808
1809    
1810    
1811    
1812    <div id="teaser-banner--text-vertical-tr" class="cmp-container">
1813        
1814        <div class="text vyvgarthcp-text--patient-portrayal-vertical-tr vyvgarthcp-color--white">
1815<div id="text-8dbc5b8359" class="cmp-text">
1816    <p>Patient portrayal</p>
1817
1818</div>
1819
1820    
1821
1822</div>
1823
1824        
1825    </div>
1826
1827</div>
1828<div class="container responsivegrid vyvgarthcp-container--fullbleed vyvgarthcp-container--section-gutter">
1829
1830    
1831    <div id="container-6592029475" class="cmp-container" style="background-color:#022A47;">
1832        
1833
1834
1835<div class="aem-Grid aem-Grid--12 aem-Grid--small--12 aem-Grid--default--12 aem-Grid--xsmall--12 ">
1836    
1837    <div class="container responsivegrid vyvgarthcp-container--content-gutter aem-GridColumn--small--none aem-GridColumn--default--none aem-GridColumn--offset--xsmall--1 aem-GridColumn--small--10 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--offset--small--1 aem-GridColumn--default--8 aem-GridColumn--offset--default--2 aem-GridColumn--xsmall--10">
1838
1839    
1840    
1841    
1842    <div id="container-181afb9355" class="cmp-container">
1843        
1844        <div class="text vyvgarthcp-color--white vyv-spacing--bottom-sm-4">
1845<div id="text-445535216d" class="cmp-text">
1846    <h2 style="	text-align: center;
1847">Receive more information about both <b>VYVGART Hytrulo</b> and <b>VYVGART</b> for adult patients with gMG.</h2>
1848
1849</div>
1850
1851    
1852
1853</div>
1854<div class="button vyvgarthcp-button--primary __text-align-center vyvgarthcp-button--rounded-r4">
1855<a id="button-b16fb33dcf" class="cmp-button" href="#contact-a-rep" target="_self">
1856    
1857    
1858
1859    <span class="cmp-button__text">Contact a rep</span> <!--Added context for the button text-->
1860</a>
1861</div>
1862<div class="text vyvgarthcp-text--small vyvgarthcp-color--white vyv-spacing--top-sm-4">
1863<div id="text-7f1a81944d" class="cmp-text">
1864    <p style="	text-align: center;
1865">gMG&#61;generalized myasthenia gravis.</p>
1866
1867</div>
1868
1869    
1870
1871</div>
1872
1873        
1874    </div>
1875
1876</div>
1877
1878    
1879</div>
1880
1881    </div>
1882
1883    
1884</div>
1885
1886        
1887    </div>
1888
1889</main>
1890<div class="container responsivegrid">
1891
1892    
1893    
1894    
1895    <div id="full-isi" class="cmp-container">
1896        
1897        <div class="fragment-importer">
1898    
1899    
1900        <div class="xfpage page basicpage">
1901
1902
1903    
1904    <div id="container-109957fe89" class="cmp-container">
1905        
1906
1907
1908<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 ">
1909    
1910    <div class="container responsivegrid vyvh-cidp--tray-container aem-GridColumn aem-GridColumn--default--12">
1911
1912    
1913    
1914    
1915    <div id="container-763edea7f3" class="cmp-container">
1916        
1917        <div class="tabs panelcontainer tabs-cidp tabs-cidp--tab-1-violet tabs-cidp--tab-2-teal">
1918<div id="isi" class="cmp-tabs" data-cmp-is="tabs" data-placeholder-text="false">
1919    <ol role="tablist" class="cmp-tabs__tablist" aria-multiselectable="false">
1920        
1921        <li role="tab" id="isi-item-0adbc7186a-tab" class="cmp-tabs__tab cmp-tabs__tab--active" aria-controls="isi-item-0adbc7186a-tabpanel" tabindex="0" data-cmp-hook-tabs="tab">VYVGART Hytrulo</li>
1922    
1923        
1924        <li role="tab" id="isi-item-1b4df2c8a8-tab" class="cmp-tabs__tab" aria-controls="isi-item-1b4df2c8a8-tabpanel" tabindex="-1" data-cmp-hook-tabs="tab">VYVGART</li>
1925    </ol>
1926    <div id="isi-item-0adbc7186a-tabpanel" role="tabpanel" aria-labelledby="isi-item-0adbc7186a-tab" tabindex="0" class="cmp-tabs__tabpanel cmp-tabs__tabpanel--active" data-cmp-hook-tabs="tabpanel" data-cmp-data-layer="{&#34;isi-item-0adbc7186a&#34;:{&#34;@type&#34;:&#34;argenx/components/content/tabs/item&#34;,&#34;dc:title&#34;:&#34;VYVGART Hytrulo&#34;}}"><div class="container responsivegrid">
1927
1928    
1929    <div id="container-7bbd9fd6fe" class="cmp-container">
1930        
1931
1932
1933<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 ">
1934    
1935    <div class="text vyv-text--isi vyvgarthcp-text--p-margin-bottom-xs aem-GridColumn aem-GridColumn--default--12">
1936<div id="®" class="cmp-text">
1937    <h4 class="br-none-mobile"><b>IMPORTANT SAFETY INFORMATION AND INDICATION</b></h4>
1938<h4 class="br-none-mobile"><b>CONTRAINDICATIONS</b></h4>
1939<p>VYVGART HYTRULO is contraindicated in patients with serious hypersensitivity to efgartigimod alfa products, to hyaluronidase, or to any of the excipients of VYVGART HYTRULO. Reactions have included anaphylaxis and hypotension leading to syncope. </p>
1940<h4><b>WARNINGS AND PRECAUTIONS<br />
1941</b> <b>Infections</b></h4>
1942<p>VYVGART HYTRULO may increase the risk of infection. The most common infections observed in Study 1 were urinary tract infection (10% of efgartigimod alfa-fcab-treated patients vs 5% of placebo-treated patients) and respiratory tract infections (33% of efgartigimod alfa-fcab-treated patients vs 29% of placebo-treated patients). Patients on efgartigimod alfa-fcab vs placebo had below normal levels for white blood cell counts (12% vs 5%, respectively), lymphocyte counts (28% vs 19%, respectively), and neutrophil counts (13% vs 6%, respectively). The majority of infections and hematologic abnormalities were mild to moderate in severity. Delay VYVGART HYTRULO administration in patients with an active infection until the infection has resolved; monitor for clinical signs and symptoms of infections. If serious infection occurs, administer appropriate treatment and consider withholding VYVGART HYTRULO until the infection has resolved.</p>
1943<h4><b>Immunization</b></h4>
1944<p>Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of a new treatment cycle with VYVGART HYTRULO. The safety of immunization with live vaccines and the immune response to vaccination during treatment with VYVGART HYTRULO are unknown. Because VYVGART HYTRULO causes a reduction in immunoglobulin G (IgG) levels, vaccination with live vaccines is not recommended during treatment with VYVGART HYTRULO.</p>
1945<h4><b>Hypersensitivity Reactions</b></h4>
1946<p>In clinical trials, hypersensitivity reactions, including rash, angioedema, and dyspnea were observed in patients treated with VYVGART HYTRULO or intravenous efgartigimod alfa-fcab. Urticaria was also observed in patients treated with VYVGART HYTRULO. Hypersensitivity reactions were mild or moderate, occurred within 1 hour to 3 weeks of administration. Anaphylaxis and hypotension leading to syncope have been reported in postmarketing experience with intravenous efgartigimod alfa-fcab. Anaphylaxis and hypotension occurred during or within an hour of administration and led to infusion discontinuation and in some cases to permanent treatment discontinuation. Monitor for clinical signs and symptoms of hypersensitivity reactions for at least 30 minutes after administration. If a hypersensitivity reaction occurs, the healthcare professional should institute appropriate measures if needed or the patient should seek medical attention.</p>
1947<h4><b>Infusion/Injection-Related Reactions </b></h4>
1948<p>Infusion-related reactions have been reported with intravenous efgartigimod alfa-fcab in postmarketing experience. The most frequent symptoms and signs were hypertension, chills, shivering, and thoracic, abdominal, and back pain. Infusion-related reactions occurred during or within an hour of administration and led to infusion discontinuation. If a severe infusion/injection-related reaction occurs, initiate appropriate therapy. Consider the risks and benefits of readministering VYVGART HYTRULO following a severe infusion/injection-related reaction. If a mild to moderate infusion/injection-related reaction occurs, patients may be rechallenged with close clinical observation, slower infusion/injection rates, and pre-medications.</p>
1949<h4><b>ADVERSE REACTIONS</b></h4>
1950<p>Patients with gMG: In Study 1, the most common (≥10%) adverse reactions in efgartigimod alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. In Study 2, the overall safety profile was consistent with the known safety profile of efgartigimod alfa-fcab in patients with gMG, except for nausea, which occurred in 7% of anti-acetylcholine receptor (AChR) antibody negative patients who received efgartigimod alfa-fcab compared to 5% of patients who received placebo. In Study 3, the most common (≥10%) adverse reactions in VYVGART HYTRULO- treated patients were injection site reactions and headache. Injection site reactions occurred in 38% of VYVGART HYTRULO-treated patients, including injection site rash, erythema, pruritus, bruising, pain, and urticaria. In Study 3 and its open-label extension, all injection site reactions were mild to moderate in severity and did not lead to treatment discontinuation. The majority occurred within 24 hours after administration and resolved spontaneously. Most injection site reactions occurred during the first treatment cycle, and the incidence decreased with each subsequent cycle.<br />
1951<br />
1952Patients with CIDP: In Study 4 stage B, the overall safety profile observed in patients with CIDP treated with VYVGART HYTRULO was consistent with the known safety profile of VYVGART HYTRULO and of efgartigimod alfa-fcab administered intravenously. In Study 4, injection site reactions occurred in 15% of patients treated with VYVGART HYTRULO compared to 6% of patients who received placebo. The most common of these injection site reactions were injection site bruising and injection site erythema. All injection site reactions were mild to moderate in severity. Most injection site reactions occurred during the first 3 months of treatment.</p>
1953<h4><b>USE IN SPECIFIC POPULATIONS<br />
1954 Pregnancy<br />
1955 </b><span style="	font-weight: 400;
1956">As VYVGART HYTRULO is expected to reduce maternal IgG antibody levels, reduction in passive protection to the newborn is anticipated. Risk and benefits should be considered prior to administering live vaccines to infants exposed to VYVGART HYTRULO in utero.</span></h4>
1957<h4> </h4>
1958<h4><b>Lactation<br />
1959 </b><span style="	font-weight: 400;
1960">There is no information regarding the presence of efgartigimod alfa or hyaluronidase, from administration of VYVGART HYTRULO, in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VYVGART HYTRULO and any potential adverse effects on the breastfed infant from VYVGART HYTRULO or from the underlying maternal 
1960condition.</span></h4>
1961<h4> </h4>
1962<h4><b>INDICATION<br />
1963 </b><span style="	font-weight: 400;
1964">VYVGART HYTRULO<sup>®</sup> (efgartigimod alfa and hyaluronidase-qvfc) is indicated for the treatment of adult patients with:</span></h4>
1965<ul><li style="	text-align: left;
1966">generalized myasthenia gravis (gMG)</li><li style="	text-align: left;
1967">chronic inflammatory demyelinating polyneuropathy (CIDP)</li></ul>
1968<p> </p>
1969<p><b>Please see the full <a href="https://www.argenx.com/product/vyvgart-hytrulo-prescribing-information.pdf" target="_blank" rel="noopener noreferrer">Prescribing Information</a>.</b></p>
1970<p>You may report side effects to the US Food and Drug Administration by visiting <a href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program">http://www.fda.gov/medwatch</a> or calling 1-800-FDA-1088. You may also report side effects to argenx US, Inc, at 1-833-argx411 (1-833-274-9411).</p>
1971<p><b>Dosage Forms and Strengths:</b> VYVGART Hytrulo is available as a single-dose subcutaneous injection containing: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per prefilled syringe, or 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial.</p>
1972
1973</div>
1974
1975    
1976
1977</div>
1978
1979    
1980</div>
1981
1982    </div>
1983
1984    
1985</div>
1986</div>
1987<div id="isi-item-1b4df2c8a8-tabpanel" role="tabpanel" aria-labelledby="isi-item-1b4df2c8a8-tab" tabindex="0" class="cmp-tabs__tabpanel" data-cmp-hook-tabs="tabpanel" data-cmp-data-layer="{&#34;isi-item-1b4df2c8a8&#34;:{&#34;@type&#34;:&#34;argenx/components/content/tabs/item&#34;,&#34;repo:modifyDate&#34;:&#34;2026-05-27T18:20:51Z&#34;,&#34;dc:title&#34;:&#34;VYVGART&#34;}}"><div class="container responsivegrid">
1988
1989    
1990    
1991    
1992    <div id="container-fff6eb5077" class="cmp-container">
1993        
1994        <div class="text vyv-text--isi vyvgarthcp-text--p-margin-bottom-xs">
1995<div id="text-0ff6c85701" class="cmp-text">
1996    <h4 class="br-none-mobile"><b>IMPORTANT SAFETY INFORMATION AND INDICATION<br />
1997 CONTRAINDICATIONS</b></h4>
1998<p>VYVGART is contraindicated in patients with serious hypersensitivity to efgartigimod alfa products or to any of the excipients of VYVGART. Reactions have included anaphylaxis and hypotension leading to syncope.</p>
1999<h4><b>WARNINGS AND PRECAUTIONS</b><br />
2000<b>Infection</b></h4>
2001<p>VYVGART may increase the risk of infection. The most common infections observed in Study 1 were urinary tract infection (10% for VYVGART vs 5% for placebo) and respiratory tract infections (33% for VYVGART vs 29% for placebo). Patients on VYVGART vs placebo had below normal levels for white blood cell counts (12% vs 5%, respectively), lymphocyte counts (28% vs 19%, respectively), and neutrophil counts (13% vs 6%, respectively). The majority of infections and hematologic abnormalities were mild to moderate in severity. Delay VYVGART administration in patients with an active infection until the infection has resolved; monitor for clinical signs and symptoms of infections. If serious infection occurs, administer appropriate treatment and consider withholding VYVGART until the infection has resolved.</p>
2002<h4><b>Immunization</b></h4>
2003<p>Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of a new treatment cycle with VYVGART. The safety of immunization with live vaccines and the immune response to vaccination during treatment with VYVGART are unknown. Because VYVGART causes a reduction in immunoglobulin G (IgG) levels, vaccination with live vaccines is not recommended during treatment with VYVGART.</p>
2004<h4><b>Hypersensitivity Reactions</b></h4>
2005<p>In clinical trials, hypersensitivity reactions, including rash, angioedema, and dyspnea were observed in VYVGART-treated patients. Hypersensitivity reactions were mild or moderate, occurred within 1 hour to 3 weeks of administration, and did not lead to treatment discontinuation. Anaphylaxis and hypotension leading to syncope have been reported in postmarketing experience with VYVGART. Anaphylaxis and hypotension occurred during or within an hour of administration and led to infusion discontinuation and in some cases to permanent treatment discontinuation. Monitor patients during administration and for 1 hour thereafter for clinical signs and symptoms of hypersensitivity reactions. If a hypersensitivity reaction occurs, the healthcare professional should institute appropriate measures if needed or the patient should seek medical attention.</p>
2006<h4><b>Infusion-Related Reactions</b></h4>
2007<p>Infusion-related reactions have been reported with VYVGART in postmarketing experience. The most frequent symptoms and signs were hypertension, chills, shivering, and thoracic, abdominal, and back pain. Infusion-related reactions occurred during or within an hour of administration and led to infusion discontinuation. If a severe infusion-related reaction occurs during administration, discontinue VYVGART infusion and initiate appropriate therapy. Consider the risks and benefits of readministering VYVGART following a severe infusion-related reaction. If a mild to moderate infusion-related reaction occurs, patients may be rechallenged with close clinical observation, slower infusion rates, and pre-medications.</p>
2008<h4><b>ADVERSE REACTIONS</b></h4>
2009<p>In Study 1, the most common (≥10%) adverse reactions with VYVGART-treated patients were respiratory tract infection, headache, and urinary tract infection. In Study 2, the overall safety profile was consistent with the known safety profile of VYVGART in patients with gMG, except for nausea, which occurred in 7% of anti-acetylcholine receptor (AChR) antibody negative patients who received VYVGART compared to 5% of patients who received placebo.</p>
2010<h4><b>USE IN SPECIFIC POPULATIONS</b><br />
2011<b>Pregnancy</b></h4>
2012<p>As VYVGART is expected to reduce maternal IgG antibody levels, reduction in passive protection to the newborn is anticipated. Risk and benefits should be considered prior to administering live vaccines to infants exposed to VYVGART in utero.</p>
2013<h4><b>Lactation</b></h4>
2014<p>There is no information regarding the presence of efgartigimod alfa-fcab in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VYVGART and any potential adverse effects on the breastfed infant from VYVGART or from the underlying maternal 
2014condition.</p>
2015<h4 id="indication"><b>INDICATION</b></h4>
2016<p>VYVGART® (efgartigimod alfa-fcab) is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG).</p>
2017<p><b>Please see the full <a href="https://www.argenx.com/product/vyvgart-prescribing-information.pdf">Prescribing Information</a>.</b></p>
2018<p>You may report side effects to the US Food and Drug Administration by visiting <a href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program">http://www.fda.gov/medwatch</a> or calling 1-800-FDA-1088. You may also report side effects to argenx US, Inc, at 1-833-argx411 (1-833-274-9411).</p>
2019<p><b>Dosage Form and Strength:</b> VYVGART is available as a single-dose injection for intravenous use containing 400 mg/20 mL of efgartigimod alfa-fcab per vial.</p>
2020
2021</div>
2022
2023    
2024
2025</div>
2026
2027        
2028    </div>
2029
2030</div>
2031</div>
2032
2033    
2034</div>
2035</div>
2036<div class="container responsivegrid vyvh-cidp-tray">
2037
2038    
2039    
2040    
2041    <div id="container-d2ec71ac59" class="cmp-container">
2042        
2043        <div class="button vyvh-cidp--exapnd-btn">
2044<button type="button" id="button-b53fd10e34" class="cmp-button" target="_self">
2045    
2046    
2047
2048     <!--Added context for the button text-->
2049</button>
2050</div>
2051<div class="tabs panelcontainer tabs-cidp tabs-cidp--tab-1-violet tabs-cidp--tab-2-teal">
2052<div id="tabs-3d7b80c486" class="cmp-tabs" data-cmp-is="tabs" data-placeholder-text="false">
2053    <ol role="tablist" class="cmp-tabs__tablist" aria-multiselectable="false">
2054        
2055        <li role="tab" id="tabs-3d7b80c486-item-cb5f46eb92-tab" class="cmp-tabs__tab cmp-tabs__tab--active" aria-controls="tabs-3d7b80c486-item-cb5f46eb92-tabpanel" tabindex="0" data-cmp-hook-tabs="tab">VYVGART Hytrulo</li>
2056    
2057        
2058        <li role="tab" id="tabs-3d7b80c486-item-751b8bfe00-tab" class="cmp-tabs__tab" aria-controls="tabs-3d7b80c486-item-751b8bfe00-tabpanel" tabindex="-1" data-cmp-hook-tabs="tab">VYVGART</li>
2059    </ol>
2060    <div id="tabs-3d7b80c486-item-cb5f46eb92-tabpanel" role="tabpanel" aria-labelledby="tabs-3d7b80c486-item-cb5f46eb92-tab" tabindex="0" class="cmp-tabs__tabpanel cmp-tabs__tabpanel--active" data-cmp-hook-tabs="tabpanel" data-cmp-data-layer="{&#34;tabs-3d7b80c486-item-cb5f46eb92&#34;:{&#34;@type&#34;:&#34;argenx/components/content/tabs/item&#34;,&#34;repo:modifyDate&#34;:&#34;2026-05-27T18:20:51Z&#34;,&#34;dc:title&#34;:&#34;VYVGART Hytrulo&#34;}}"><div class="container responsivegrid">
2061
2062    
2063    <div id="container-5246432ba2" class="cmp-container">
2064        
2065
2066
2067<div class="aem-Grid aem-Grid--12 aem-Grid--small--12 aem-Grid--default--12 ">
2068    
2069    <div class="text vyv-text--isi vyvgarthcp-text--p-margin-bottom-xs vyv-spacing--bottom-sm-4 vyvgarthcp-spacing--desktop-bottom--none aem-GridColumn--small--none aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--default--12">
2070<div id="text-d07c5ad4bf" class="cmp-text">
2071    <h4 class="br-none-mobile"><b>IMPORTANT SAFETY INFORMATION AND INDICATION</b></h4>
2072<h4 class="br-none-mobile"><b>CONTRAINDICATIONS</b></h4>
2073<p>VYVGART HYTRULO is contraindicated in patients with serious hypersensitivity to efgartigimod alfa products, to hyaluronidase, or to any of the excipients of VYVGART HYTRULO. Reactions have included anaphylaxis and hypotension leading to syncope. </p>
2074<h4><b>WARNINGS AND PRECAUTIONS<br />
2075</b> <b>Infections</b></h4>
2076<p>VYVGART HYTRULO may increase the risk of infection. The most common infections observed in Study 1 were urinary tract infection (10% of efgartigimod alfa-fcab-treated patients vs 5% of placebo-treated patients) and respiratory tract infections (33% of efgartigimod alfa-fcab-treated patients vs 29% of placebo-treated patients). Patients on efgartigimod alfa-fcab vs placebo had below normal levels for white blood cell counts (12% vs 5%, respectively), lymphocyte counts (28% vs 19%, respectively), and neutrophil counts (13% vs 6%, respectively). The majority of infections and hematologic abnormalities were mild to moderate in severity. Delay VYVGART HYTRULO administration in patients with an active infection until the infection has resolved; monitor for clinical signs and symptoms of infections. If serious infection occurs, administer appropriate treatment and consider withholding VYVGART HYTRULO until the infection has resolved.</p>
2077<h4><b>Immunization</b></h4>
2078<p>Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of a new treatment cycle with VYVGART HYTRULO. The safety of immunization with live vaccines and the immune response to vaccination during treatment with VYVGART HYTRULO are unknown. Because VYVGART HYTRULO causes a reduction in immunoglobulin G (IgG) levels, vaccination with live vaccines is not recommended during treatment with VYVGART HYTRULO.</p>
2079<h4><b>Hypersensitivity Reactions</b></h4>
2080<p>In clinical trials, hypersensitivity reactions, including rash, angioedema, and dyspnea were observed in patients treated with VYVGART HYTRULO or intravenous efgartigimod alfa-fcab. Urticaria was also observed in patients treated with VYVGART HYTRULO. Hypersensitivity reactions were mild or moderate, occurred within 1 hour to 3 weeks of administration. Anaphylaxis and hypotension leading to syncope have been reported in postmarketing experience with intravenous efgartigimod alfa-fcab. Anaphylaxis and hypotension occurred during or within an hour of administration and led to infusion discontinuation and in some cases to permanent treatment discontinuation. Monitor for clinical signs and symptoms of hypersensitivity reactions for at least 30 minutes after administration. If a hypersensitivity reaction occurs, the healthcare professional should institute appropriate measures if needed or the patient should seek medical attention.</p>
2081<h4><b>Infusion/Injection-Related Reactions </b></h4>
2082<p>Infusion-related reactions have been reported with intravenous efgartigimod alfa-fcab in postmarketing experience. The most frequent symptoms and signs were hypertension, chills, shivering, and thoracic, abdominal, and back pain. Infusion-related reactions occurred during or within an hour of administration and led to infusion discontinuation. If a severe infusion/injection-related reaction occurs, initiate appropriate therapy. Consider the risks and benefits of readministering VYVGART HYTRULO following a severe infusion/injection-related reaction. If a mild to moderate infusion/injection-related reaction occurs, patients may be rechallenged with close clinical observation, slower infusion/injection rates, and pre-medications.</p>
2083<h4><b>ADVERSE REACTIONS</b></h4>
2084<p>Patients with gMG: In Study 1, the most common (≥10%) adverse reactions in efgartigimod alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. In Study 2, the overall safety profile was consistent with the known safety profile of efgartigimod alfa-fcab in patients with gMG, except for nausea, which occurred in 7% of anti-acetylcholine receptor (AChR) antibody negative patients who received efgartigimod alfa-fcab compared to 5% of patients who received placebo. In Study 3, the most common (≥10%) adverse reactions in VYVGART HYTRULO- treated patients were injection site reactions and headache. Injection site reactions occurred in 38% of VYVGART HYTRULO-treated patients, including injection site rash, erythema, pruritus, bruising, pain, and urticaria. In Study 3 and its open-label extension, all injection site reactions were mild to moderate in severity and did not lead to treatment discontinuation. The majority occurred within 24 hours after administration and resolved spontaneously. Most injection site reactions occurred during the first treatment cycle, and the incidence decreased with each subsequent cycle.<br />
2085<br />
2086Patients with CIDP: In Study 4 stage B, the overall safety profile observed in patients with CIDP treated with VYVGART HYTRULO was consistent with the known safety profile of VYVGART HYTRULO and of efgartigimod alfa-fcab administered intravenously. In Study 4, injection site reactions occurred in 15% of patients treated with VYVGART HYTRULO compared to 6% of patients who received placebo. The most common of these injection site reactions were injection site bruising and injection site erythema. All injection site reactions were mild to moderate in severity. Most injection site reactions occurred during the first 3 months of treatment.</p>
2087<h4><b>USE IN SPECIFIC POPULATIONS<br />
2088 Pregnancy<br />
2089 </b><span style="	font-weight: 400;
2090">As VYVGART HYTRULO is expected to reduce maternal IgG antibody levels, reduction in passive protection to the newborn is anticipated. Risk and benefits should be considered prior to administering live vaccines to infants exposed to VYVGART HYTRULO in utero.</span></h4>
2091<h4> </h4>
2092<h4><b>Lactation<br />
2093 </b><span style="	font-weight: 400;
2094">There is no information regarding the presence of efgartigimod alfa or hyaluronidase, from administration of VYVGART HYTRULO, in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VYVGART HYTRULO and any potential adverse effects on the breastfed infant from VYVGART HYTRULO or from the underlying maternal 
2094condition.</span></h4>
2095<h4> </h4>
2096
2097</div>
2098
2099    
2100
2101</div>
2102<div class="text vyv-text--isi vyvgarthcp-text--p-margin-bottom-xs aem-GridColumn aem-GridColumn--default--12">
2103<div id="text-ddeff36315" class="cmp-text">
2104    <h4><b>INDICATION<br />
2105 </b><span style="	font-weight: 400;
2106">VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc) is indicated for the treatment of adult patients with:</span></h4>
2107<ul><li style="	text-align: left;
2108">generalized myasthenia gravis (gMG)</li><li style="	text-align: left;
2109">chronic inflammatory demyelinating polyneuropathy (CIDP)</li></ul>
2110<p> </p>
2111<p><b style="">Please see the full <a href="https://www.argenx.com/product/vyvgart-hytrulo-prescribing-information.pdf" target="_blank" rel="noopener noreferrer">Prescribing Information</a>.</b></p>
2112<p>You may report side effects to the US Food and Drug Administration by visiting <a href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program">http://www.fda.gov/medwatch</a> or calling 1-800-FDA-1088. You may also report side effects to argenx US, Inc, at 1-833-argx411 (1-833-274-9411).</p>
2113<p><b>Dosage Forms and Strengths:</b> VYVGART Hytrulo is available as a single-dose subcutaneous injection containing: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per prefilled syringe, or 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial.</p>
2114
2115</div>
2116
2117    
2118
2119</div>
2120
2121    
2122</div>
2123
2124    </div>
2125
2126    
2127</div>
2128</div>
2129<div id="tabs-3d7b80c486-item-751b8bfe00-tabpanel" role="tabpanel" aria-labelledby="tabs-3d7b80c486-item-751b8bfe00-tab" tabindex="0" class="cmp-tabs__tabpanel" data-cmp-hook-tabs="tabpanel" data-cmp-data-layer="{&#34;tabs-3d7b80c486-item-751b8bfe00&#34;:{&#34;@type&#34;:&#34;argenx/components/content/tabs/item&#34;,&#34;repo:modifyDate&#34;:&#34;2026-05-27T18:20:51Z&#34;,&#34;dc:title&#34;:&#34;VYVGART&#34;}}"><div class="container responsivegrid">
2130
2131    
2132    <div id="container-ebbb56f5b3" class="cmp-container">
2133        
2134
2135
2136<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 ">
2137    
2138    <div class="text vyv-text--isi vyvgarthcp-text--p-margin-bottom-xs vyv-spacing--bottom-sm-4 vyvgarthcp-spacing--desktop-bottom--none aem-GridColumn--default--none aem-GridColumn aem-GridColumn--default--12 aem-GridColumn--offset--default--0">
2139<div id="text-f34f132268" class="cmp-text">
2140    <h4 class="br-none-mobile"><b>IMPORTANT SAFETY INFORMATION AND INDICATION</b></h4>
2141<h4 class="br-none-mobile"><b>CONTRAINDICATIONS</b></h4>
2142<p>VYVGART is contraindicated in patients with serious hypersensitivity to efgartigimod alfa products or to any of the excipients of VYVGART. Reactions have included anaphylaxis and hypotension leading to syncope.</p>
2143<h4><b>WARNINGS AND PRECAUTIONS</b><br />
2144<b>Infection</b></h4>
2145<p>VYVGART may increase the risk of infection. The most common infections observed in Study 1 were urinary tract infection (10% for VYVGART vs 5% for placebo) and respiratory tract infections (33% for VYVGART vs 29% for placebo). Patients on VYVGART vs placebo had below normal levels for white blood cell counts (12% vs 5%, respectively), lymphocyte counts (28% vs 19%, respectively), and neutrophil counts (13% vs 6%, respectively). The majority of infections and hematologic abnormalities were mild to moderate in severity. Delay VYVGART administration in patients with an active infection until the infection has resolved; monitor for clinical signs and symptoms of infections. If serious infection occurs, administer appropriate treatment and consider withholding VYVGART until the infection has resolved.</p>
2146<h4><b>Immunization</b></h4>
2147<p>Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of a new treatment cycle with VYVGART. The safety of immunization with live vaccines and the immune response to vaccination during treatment with VYVGART are unknown. Because VYVGART causes a reduction in immunoglobulin G (IgG) levels, vaccination with live vaccines is not recommended during treatment with VYVGART.</p>
2148<h4><b>Hypersensitivity Reactions</b></h4>
2149<p>In clinical trials, hypersensitivity reactions, including rash, angioedema, and dyspnea were observed in VYVGART-treated patients. Hypersensitivity reactions were mild or moderate, occurred within 1 hour to 3 weeks of administration, and did not lead to treatment discontinuation. Anaphylaxis and hypotension leading to syncope have been reported in postmarketing experience with VYVGART. Anaphylaxis and hypotension occurred during or within an hour of administration and led to infusion discontinuation and in some cases to permanent treatment discontinuation. Monitor patients during administration and for 1 hour thereafter for clinical signs and symptoms of hypersensitivity reactions. If a hypersensitivity reaction occurs, the healthcare professional should institute appropriate measures if needed or the patient should seek medical attention.</p>
2150<h4><b>Infusion-Related Reactions</b></h4>
2151<p>Infusion-related reactions have been reported with VYVGART in postmarketing experience. The most frequent symptoms and signs were hypertension, chills, shivering, and thoracic, abdominal, and back pain. Infusion-related reactions occurred during or within an hour of administration and led to infusion discontinuation. If a severe infusion-related reaction occurs during administration, discontinue VYVGART infusion and initiate appropriate therapy. Consider the risks and benefits of readministering VYVGART following a severe infusion-related reaction. If a mild to moderate infusion-related reaction occurs, patients may be rechallenged with close clinical observation, slower infusion rates, and pre-medications.</p>
2152<h4><b>ADVERSE REACTIONS</b></h4>
2153<p>In Study 1, the most common (≥10%) adverse reactions with VYVGART-treated patients were respiratory tract infection, headache, and urinary tract infection. In Study 2, the overall safety profile was consistent with the known safety profile of VYVGART in patients with gMG, except for nausea, which occurred in 7% of anti-acetylcholine receptor (AChR) antibody negative patients who received VYVGART compared to 5% of patients who received placebo.</p>
2154<h4><b>USE IN SPECIFIC POPULATIONS</b><br />
2155<b>Pregnancy</b></h4>
2156<p>As VYVGART is expected to reduce maternal IgG antibody levels, reduction in passive protection to the newborn is anticipated. Risk and benefits should be considered prior to administering live vaccines to infants exposed to VYVGART in utero.</p>
2157<h4><b>Lactation</b></h4>
2158<p>There is no information regarding the presence of efgartigimod alfa-fcab in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VYVGART and any potential adverse effects on the breastfed infant from VYVGART or from the underlying maternal 
2158condition.</p>
2159
2160</div>
2161
2162    
2163
2164</div>
2165<div class="text vyv-text--isi aem-GridColumn aem-GridColumn--default--12">
2166<div id="text-25ad042d61" class="cmp-text">
2167    <h4 id="indication"><b>INDICATION</b></h4>
2168<p>VYVGART® (efgartigimod alfa-fcab) is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG).</p>
2169<p><b>Please see the full <a href="https://www.argenx.com/product/vyvgart-prescribing-information.pdf">Prescribing Information</a>.</b></p>
2170<p>You may report side effects to the US Food and Drug Administration by visiting <a href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program">http://www.fda.gov/medwatch</a> or calling 1-800-FDA-1088. You may also report side effects to argenx US, Inc, at 1-833-argx411 (1-833-274-9411).</p>
2171<p><b>Dosage Form and Strength:</b> VYVGART is available as a single-dose injection for intravenous use containing 400 mg/20 mL of efgartigimod alfa-fcab per vial.</p>
2172
2173</div>
2174
2175    
2176
2177</div>
2178
2179    
2180</div>
2181
2182    </div>
2183
2184    
2185</div>
2186</div>
2187
2188    
2189</div>
2190</div>
2191
2192        
2193    </div>
2194
2195</div>
2196
2197        
2198    </div>
2199
2200</div>
2201
2202    
2203</div>
2204
2205    </div>
2206
2207    
2208</div>
2209
2210    
2211
2212
2213    
2214</div>
2215
2216        
2217    </div>
2218
2219</div>
2220<div class="container responsivegrid">
2221
2222    
2223    
2224    
2225    <div id="container-6e8e7df58e" class="cmp-container">
2226        
2227        <div class="text vyvgarthcp-text--references">
2228<div id="text-3c3289285f" class="cmp-text">
2229    <p><b>References:</b> <b>1.</b> VYVGART. Prescribing information. argenx US Inc; 2026. <b>2.</b> VYVGART Hytrulo. Prescribing information. argenx US Inc; 2026.</p>
2230
2231</div>
2232
2233    
2234
2235</div>
2236
2237        
2238    </div>
2239
2240</div>
2241<footer class="container responsivegrid">
2242
2243    
2244    
2245    
2246    <div id="container-d72ada74a1" class="cmp-container">
2247        
2248        <div class="container responsivegrid">
2249
2250    
2251    
2252    
2253    <div id="container-48acb4d21d" class="cmp-container">
2254        
2255        
2256        
2257    </div>
2258
2259</div>
2260<div class="experiencefragment">
2261<div id="experiencefragment-f5d4fdef32" class="cmp-experiencefragment cmp-experiencefragment--footer-links">
2262
2263
2264    
2265    <div id="container-16ceae92b7" class="cmp-container">
2266        
2267
2268
2269<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 ">
2270    
2271    <div class="text vyvh-cidp-text--footer vyvgarthcp-text--medium aem-GridColumn aem-GridColumn--default--12">
2272<div id="text-16870a934d" class="cmp-text">
2273    <ul><li><a href="https://argenx.com/about" target="_blank" rel="noopener noreferrer">About argenx</a></li><li><a href="https://argenxmedical.com/" target="_blank" rel="noopener noreferrer">Medical Affairs</a></li><li><a href="https://www.argenx.com/contact-us" target="_blank" rel="noopener noreferrer">Contact us</a></li><li><a href="https://www.argenx.com/privacy-policy" target="_blank" rel="noopener noreferrer">Privacy Policy</a></li><li><a href="https://www.argenx.com/cookie-policy" target="_blank" rel="noopener noreferrer">Cookie Policy</a></li></ul>
2274
2275</div>
2276
2277    
2278
2279</div>
2280
2281    
2282</div>
2283
2284    </div>
2285
2286    
2287</div>
2288
2289    
2290</div>
2291<div class="container responsivegrid">
2292
2293    
2294    <div id="vyvgarthcp-main--footer" class="cmp-container">
2295        
2296
2297
2298<div class="aem-Grid aem-Grid--12 aem-Grid--small--12 aem-Grid--default--12 aem-Grid--xsmall--12 aem-Grid--phone--12 ">
2299    
2300    <div class="container responsivegrid aem-GridColumn--small--none aem-GridColumn--default--none aem-GridColumn--phone--none aem-GridColumn--phone--12 aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--offset--phone--0 aem-GridColumn--offset--default--0 aem-GridColumn--default--2">
2301
2302    
2303    
2304    
2305    <div id="container-f1ce373c3e" class="cmp-container">
2306        
2307        <div class="image">
2308<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/vyvgart/us/en/hcp/gmg/enroll-patients.coreimg{.width}.svg/structure/jcr:content/root/container_2013501416/container/container_copy/image_copy/1668012062403/argenx-logo-rgb.svg" data-asset="/content/dam/brand-portal/downloads/argenx/logos/rgb/argenx_logo_RGB.svg" data-asset-id="c15b310a-7b9f-4598-9b7b-29c6c5e6c937" data-title="argenx logo" id="footer-argenx-logo" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject">
2309    <a class="cmp-image__link" href="https://www.argenx.com/" data-cmp-hook-image="link">
2310        
2311            
2312            <img src="/content/vyvgart/us/en/hcp/gmg/enroll-patients.coreimg.svg/stru
2312cture/_jcr_content/root/container_2013501416/container/container_copy/image_copy/1668012062403/argenx-logo-rgb.svg" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt="argenx logo"/>
2313            
2314        
2315    </a>
2316    
2317    
2318</div>
2319
2320    
2321
2322</div>
2323
2324        
2325    </div>
2326
2327</div>
2328<div class="container responsivegrid aem-GridColumn--small--none aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--default--9 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--xsmall--11 aem-GridColumn--offset--default--1">
2329
2330    
2331    
2332    
2333    <div id="container-2c60f4842c" class="cmp-container">
2334        
2335        <div class="text">
2336<div id="text-1f17661c71" class="cmp-text">
2337    <p>For US audiences only.<br />
2338VYVGART and VYVGART Hytrulo are registered trademarks of argenx.<br />
2339© 2026 argenx US-ESC-23-00055 V10 05/2026. All Rights Reserved.</p>
2340
2341</div>
2342
2343    
2344
2345</div>
2346
2347        
2348    </div>
2349
2350</div>
2351
2352    
2353</div>
2354
2355    </div>
2356
2357    
2358</div>
2359
2360        
2361    </div>
2362
2363</footer>
2364<div class="overlay-modal">
2365     <!-- Load vimeo player API -->
2366    
2367    <div id="modal__contact-a-rep-thank-you" class="cmp-overlay-modal-pre__main-wrapper" data-modal-animation="none" aria-modal="true" role="dialog" aria-hidden='true'>
2368        <div class="cmp-overlay-modal-pre__main-backdrop"></div>
2369        <div class="cmp-overlay-modal-pre__main-modal">
2370            <div class="cmp-overlay-modal-pre__main-modal-close-button" tabindex="0">
2371                <span></span>
2372                <span></span>
2373            </div>
2374            <div class="cmp-overlay-modal-pre__main-modal-content">
2375
2376                
2377
2378                
2379
2380                
2381                 <!-- Experience Fragment start -->
2382                <div id="overlay-modal-408ec76965" class="cmp-experiencefragment cmp-experiencefragment--contact-a-rep">
2383
2384
2385    
2386    <div id="container-0adec01ce0" class="cmp-container">
2387        
2388
2389
2390<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 ">
2391    
2392    <div class="container responsivegrid vyvgarthcp-container--modal __contact-a-rep __close aem-GridColumn aem-GridColumn--default--12">
2393
2394    
2395    <div id="container-b619e614b2" class="cmp-container">
2396        
2397
2398
2399<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 ">
2400    
2401    <div class="button aem-GridColumn aem-GridColumn--default--12">
2402<button type="button" id="modal-x" class="cmp-button" target="_self">
2403    
2404    <span class="cmp-button__icon cmp-button__icon--modal-x" aria-hidden="true"></span>
2405
2406     <!--Added context for the button text-->
2407</button>
2408</div>
2409<div class="container responsivegrid aem-GridColumn aem-GridColumn--default--12">
2410
2411    
2412    <div id="wrapper" class="cmp-container">
2413        
2414
2415
2416<div class="aem-Grid aem-Grid--12 aem-Grid--small--12 aem-Grid--default--12 aem-Grid--xsmall--12 aem-Grid--medium--12 ">
2417    
2418    <div class="container responsivegrid aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--xsmall--12 aem-GridColumn--offset--default--0 aem-GridColumn--offset--medium--0 aem-GridColumn--small--hide aem-GridColumn--medium--12 aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--default--4 aem-GridColumn--medium--hide aem-GridColumn--xsmall--hide">
2419
2420    
2421    
2422    
2423    <div id="container-ba17771e46" class="cmp-container">
2424        
2425        <div class="image">
2426
2427
2428    
2429
2430</div>
2431
2432        
2433    </div>
2434
2435</div>
2436<div class="container responsivegrid aem-GridColumn--small--none aem-GridColumn--medium--none aem-GridColumn--offset--xsmall--0 aem-GridColumn--default--none aem-GridColumn--xsmall--12 aem-GridColumn--offset--default--0 aem-GridColumn--offset--medium--0 aem-GridColumn--xsmall--none aem-GridColumn--medium--12 aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--default--8">
2437
2438    
2439    
2440    
2441    <div id="container-3c2ccd0cbf" class="cmp-container">
2442        
2443        <div class="text">
2444<div id="text-61fc44831f" class="cmp-text">
2445    <h6 class="vyvgarthcp-spacing--bottom-xsmall"><b>CONTACT A REP</b></h6>
2446<h3>Thank you! </h3>
2447<p>An argenx representative will reach out to you soon, so keep an eye on your inbox!</p>
2448
2449</div>
2450
2451    
2452
2453</div>
2454
2455        
2456    </div>
2457
2458</div>
2459
2460    
2461</div>
2462
2463    </div>
2464
2465    
2466</div>
2467
2468    
2469</div>
2470
2471    </div>
2472
2473    
2474</div>
2475
2476    
2477</div>
2478
2479    </div>
2480
2481    
2482</div>
2483                <!-- Video Section start -->
2484                
2485                <!-- Video Section end -->
2486
2487                <!-- Content for the post video screen start -->
2488                
2489                <!-- Content for the post video screen end -->
2490            </div>
2491        </div>
2492    </div>
2493
2494
2495
2496    
2497</div>
2498<div class="overlay-modal">
2499     <!-- Load vimeo player API -->
2500    
2501    <div id="modal__hcp-confirmation" class="cmp-overlay-modal-pre__main-wrapper" aria-modal="true" role="dialog" aria-hidden='true'>
2502        <div class="cmp-overlay-modal-pre__main-backdrop"></div>
2503        <div class="cmp-overlay-modal-pre__main-modal">
2504            <div class="cmp-overlay-modal-pre__main-modal-close-button" tabindex="0">
2505                <span></span>
2506                <span></span>
2507            </div>
2508            <div class="cmp-overlay-modal-pre__main-modal-content">
2509
2510                
2511
2512                
2513
2514                
2515                 <!-- Experience Fragment start -->
2516                <div id="overlay-modal-929d4cd853" class="cmp-experiencefragment cmp-experiencefragment--hcp-confirmation">
2517
2518
2519    
2520    <div id="container-032a197f91" class="cmp-container">
2521        
2522
2523
2524<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 ">
2525    
2526    <div class="container responsivegrid vyvgarthcp-container--modal __interstitial-hcp-confirmation cmp-external-site-popup-warning __close aem-GridColumn aem-GridColumn--default--12">
2527
2528    
2529    
2530    
2531    <div id="container-3d0e61aa82" class="cmp-container">
2532        
2533        <div class="image">
2534<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/experience-fragments/vyvgart/us/en/hcp/hcp-confirmation/master/_jcr_content/root/container_copy/image_copy_copy_copy.coreimg.90{.width}.png/1747103065110/co-branded-logos.png" data-cmp-widths="768,1200,1440,1980" data-asset="/content/dam/vyvgart/hcp/logos/co-branded-logos.png" data-title="co-branded logo" id="clickout-modal-logo" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject">
2535    
2536        <noscript data-cmp-hook-image="noscript">
2537            
2538            <img src="/content/experience-fragments/vyvgart/us/en/hcp/hcp-confirmation/master/_jcr_content/root/container_copy/image_copy_copy_copy.coreimg.png/1747103065110/co-branded-logos.png" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt="co-branded logo"/>
2539            
2540        </noscript>
2541    
2542    
2543    
2544</div>
2545
2546    
2547
2548</div>
2549<div class="text vyv-spacing--top-sm-4 vyv-spacing--bottom-sm-4">
2550<div id="text-e2629a892a" class="cmp-text">
2551    <h3>This information is intended for US<br />
2552healthcare professionals only</h3>
2553
2554</div>
2555
2556    
2557
2558</div>
2559<div class="button vyvgarthcp-button--secondary vyvgarthcp-button--rounded-r4">
2560<a id="modal-x" class="cmp-button" href="#" target="_self">
2561    
2562    
2563
2564    <span class="cmp-button__text">I am a US healthcare professional</span> <!--Added context for the button text-->
2565</a>
2566</div>
2567<div class="button vyv-button--ghost vyvgarthcp-button--rounded-r4">
2568<a id="not-hcp" class="cmp-button" href="https://vyvgart.com/" target="_self">
2569    
2570    
2571
2572    <span class="cmp-button__text">I am not a US healthcare professional </span> <!--Added context for the button text-->
2573</a>
2574</div>
2575
2576        
2577    </div>
2578
2579</div>
2580
2581    
2582</div>
2583
2584    </div>
2585
2586    
2587</div>
2588                <!-- Video Section start -->
2589                
2590                <!-- Video Section end -->
2591
2592                <!-- Content for the post video screen start -->
2593                
2594                <!-- Content for the post video screen end -->
2595            </div>
2596        </div>
2597    </div>
2598
2599
2600
2601    
2602</div>
2603<div class="overlay-modal">
2604     <!-- Load vimeo player API -->
2605    
2606    <div id="modal__search" class="cmp-overlay-modal-pre__main-wrapper" aria-modal="true" role="dialog" aria-hidden='true'>
2607        <div class="cmp-overlay-modal-pre__main-backdrop"></div>
2608        <div class="cmp-overlay-modal-pre__main-modal">
2609            <div class="cmp-overlay-modal-pre__main-modal-close-button" tabindex="0">
2610                <span></span>
2611                <span></span>
2612            </div>
2613            <div class="cmp-overlay-modal-pre__main-modal-content">
2614
2615                
2616
2617                
2618
2619                
2620                 <!-- Experience Fragment start -->
2621                <div id="overlay-modal-ded45c8553" class="cmp-experiencefragment cmp-experiencefragment--search-modal">
2622
2623
2624    
2625    <div id="container-261eb48ebe" class="cmp-container">
2626        
2627
2628
2629<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 ">
2630    
2631    <div class="container responsivegrid vyvgarthcp-container--modal __close aem-GridColumn aem-GridColumn--default--12">
2632
2633    
2634    <div id="search-modal" class="cmp-container">
2635        
2636
2637
2638<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 ">
2639    
2640    <div class="button aem-GridColumn aem-GridColumn--default--12">
2641<button type="button" id="modal-x" class="cmp-button" target="_self">
2642    
2643    <span class="cmp-button__icon cmp-button__icon--modal-x" aria-hidden="true"></span>
2644
2645     <!--Added context for the button text-->
2646</button>
2647</div>
2648<div class="text vyv-spacing--bottom-sm-7 vyvgarthcp-text--font-weight-sm aem-GridColumn aem-GridColumn--default--12">
2649<div id="text-5e2103692e" class="cmp-text">
2650    <h3 style="	text-align: center;
2651	margin-top: 0;
2652">Search for:</h3>
2653
2654</div>
2655
2656    
2657
2658</div>
2659<div class="container responsivegrid aem-GridColumn aem-GridColumn--default--12">
2660<form method="POST" action="/gmg/enroll-patients" id="new_form" name="new_form" enctype="multipart/form-data" class="cmp-form aem-Grid aem-Grid--12 aem-Grid--small--12 aem-Grid--default--12 aem-Grid--xsmall--12">
2661    
2662    <input type="hidden" name=":formstart" value="/content/experience-fragments/vyvgart/us/en/hcp/search-modal/master/jcr:content/root/container_
2662copy_copy_/container"/>
2663    <input type="hidden" name="_charset_" value="utf-8"/>
2664    
2665    <div class="text aem-GridColumn aem-GridColumn--default--12">
2666  <div class="cmp-form-text" data-cmp-is="formText">
2667 
2668 
2669 
2670 <input class="cmp-form-text__text" data-cmp-hook-form-text="input" aria-label="search" type="text" id="form-text-1923461428" name="search" value="enter search term"/>
2671</div></div>
2672<div class="button vyv-button--center-mobile aem-GridColumn--small--none aem-GridColumn--offset--xsmall--0 aem-GridColumn--xsmall--12 aem-GridColumn--xsmall--none aem-GridColumn aem-GridColumn--small--12 aem-GridColumn--offset--small--0 aem-GridColumn--default--12">
2673<button type="BUTTON" id="form-button-1109831993" class="cmp-form-button">Search</button>
2674</div>
2675
2676    
2677</form>
2678</div>
2679
2680    
2681</div>
2682
2683    </div>
2684
2685    
2686</div>
2687
2688    
2689</div>
2690
2691    </div>
2692
2693    
2694</div>
2695                <!-- Video Section start -->
2696                
2697                <!-- Video Section end -->
2698
2699                <!-- Content for the post video screen start -->
2700                
2701                <!-- Content for the post video screen end -->
2702            </div>
2703        </div>
2704    </div>
2705
2706
2707
2708    
2709</div>
2710<div class="overlay-modal">
2711     <!-- Load vimeo player API -->
2712    
2713    <div id="modal__lightbox" class="cmp-overlay-modal-pre__main-wrapper" aria-modal="true" role="dialog" aria-hidden='true'>
2714        <div class="cmp-overlay-modal-pre__main-backdrop"></div>
2715        <div class="cmp-overlay-modal-pre__main-modal">
2716            <div class="cmp-overlay-modal-pre__main-modal-close-button" tabindex="0">
2717                <span></span>
2718                <span></span>
2719            </div>
2720            <div class="cmp-overlay-modal-pre__main-modal-content">
2721
2722                
2723
2724                
2725
2726                
2727                 <!-- Experience Fragment start -->
2728                <div id="overlay-modal-3891c2416e" class="cmp-experiencefragment cmp-experiencefragment--lightbox-modal">
2729
2730
2731    
2732    <div id="container-03977db68a" class="cmp-container">
2733        
2734
2735
2736<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 ">
2737    
2738    <div class="container responsivegrid vyvgarthcp-container--modal __close aem-GridColumn aem-GridColumn--default--12">
2739
2740    
2741    <div id="container-cb28261ca3" class="cmp-container">
2742        
2743
2744
2745<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 ">
2746    
2747    <div class="button aem-GridColumn aem-GridColumn--default--12">
2748<button type="button" id="modal-x" class="cmp-button" target="_self">
2749    
2750    <span class="cmp-button__icon cmp-button__icon--modal-x-white" aria-hidden="true"></span>
2751
2752     <!--Added context for the button text-->
2753</button>
2754</div>
2755
2756    
2757</div>
2758
2759    </div>
2760
2761    
2762</div>
2763
2764    
2765</div>
2766
2767    </div>
2768
2769    
2770</div>
2771                <!-- Video Section start -->
2772                
2773                <!-- Video Section end -->
2774
2775                <!-- Content for the post video screen start -->
2776                
2777                <!-- Content for the post video screen end -->
2778            </div>
2779        </div>
2780    </div>
2781
2782
2783
2784    
2785</div>
2786<div class="overlay-modal">
2787     <!-- Load vimeo player API -->
2788    
2789    <div id="modal__videos" class="cmp-overlay-modal-pre__main-wrapper" aria-modal="true" role="dialog" aria-hidden='true'>
2790        <div class="cmp-overlay-modal-pre__main-backdrop"></div>
2791        <div class="cmp-overlay-modal-pre__main-modal">
2792            <div class="cmp-overlay-modal-pre__main-modal-close-button" tabindex="0">
2793                <span></span>
2794                <span></span>
2795            </div>
2796            <div class="cmp-overlay-modal-pre__main-modal-content">
2797
2798                
2799
2800                
2801
2802                
2803                 <!-- Experience Fragment start -->
2804                <div id="overlay-modal-7fb91286f5" class="cmp-experiencefragment cmp-experiencefragment--video-playlist-modal">
2805
2806
2807    
2808    <div id="container-24fb0ced66" class="cmp-container">
2809        
2810
2811
2812<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 ">
2813    
2814    <div class="container responsivegrid vyvgarthcp-container--modal __video-playlist __close aem-GridColumn aem-GridColumn--default--12">
2815
2816    
2817    
2818    
2819    <div id="container-ed233e20fb" class="cmp-container">
2820        
2821        <div class="button">
2822<button type="button" id="modal-x" class="cmp-button" target="_self">
2823    
2824    <span class="cmp-button__icon cmp-button__icon--modal-x-white" aria-hidden="true"></span>
2825
2826     <!--Added context for the button text-->
2827</button>
2828</div>
2829<div class="video-playlist">
2829  <div class="cmp-video">
2830  <section class="cmp-video__main">
2831    <div class="cmp-video__player-container">
2832      <div class="cmp-video__section-wrapper">
2833        <div class="cmp-video__section-block">
2834          <h2>Video Playlist</h2>
2835          <h3 class="cmp-video__text">
2836            
2837          </h3>
2838        </div>
2839      </div>
2840
2841      <div class="cmp-video__player" data-vimeo-url="https://player.vimeo.com/video/">
2842        <iframe width="640" height="361" frameborder="0" allow="autoplay; fullscreen"></iframe>
2843      </div>
2844
2845
2846      <div id="demo" class="carousel slide" data-ride="carousel">
2847  <!-- Indicators -->
2848  <ul class="carousel-indicators">
2849    <li data-target="#demo" data-slide-to="0" class="active"></li>
2850    <li data-target="#demo" data-slide-to="1"></li>
2851    <li data-target="#demo" data-slide-to="2"></li>
2852  </ul>
2853
2854  <!-- The slideshow -->
2855  
2856
2857  <!-- Left and right controls -->
2858  <a class="carousel-control-prev" href="#demo" data-slide="prev">
2859    <span class="carousel-control-prev-icon"></span>
2860  </a>
2861  <a class="carousel-control-next" href="#demo" data-slide="next">
2862    <span class="carousel-control-next-icon"></span>
2863  </a>
2864
2865</div>
2866
2867    </div>
2868  </section>
2869</div>
2870
2871    
2872
2873</div>
2874<div class="container responsivegrid">
2875
2876    
2877    
2878    
2879    <div id="isi-container" class="cmp-container">
2880        
2881        <div class="text">
2882<div id="text-510f99ae2e" class="cmp-text">
2883    <h4>IMPORTANT SAFETY INFORMATION AND INDICATION<br />
2884CONTRAINDICATIONS</h4>
2885<p>VYVGART and VYVGART HYTRULO are contraindicated in patients with serious hypersensitivity to efgartigimod alfa products or to any of the excipients of VYVGART or VYVGART HYTRULO, respectively. VYVGART HYTRULO is also contraindicated in patients with serious hypersensitivity to hyaluronidase. Reactions have included anaphylaxis and hypotension leading to syncope.</p>
2886<h4>WARNINGS AND PRECAUTIONS<br />
2887Infections</h4>
2888<p>VYVGART and VYVGART HYTRULO may increase the risk of infection. The most common infections observed in Study 1 were urinary tract infection (10% of efgartigimod alfa-fcab-treated patients vs 5% of placebo-treated patients) and respiratory tract infection (33% of efgartigimod alfa-fcab-treated patients vs 29% of placebo-treated patients). Patients on efgartigimod alfa-fcab vs placebo had below normal levels for white blood cell counts (12% vs 5%, respectively), lymphocyte counts (28% vs 19%, respectively), and neutrophil counts (13% vs 6%, respectively). The majority of infections and hematologic abnormalities were mild to moderate in severity. Delay the administration of VYVGART or VYVGART HYTRULO in patients with an active infection until the infection has resolved; monitor for clinical signs and symptoms of infections. If serious infection occurs, administer appropriate treatment and consider withholding treatment with VYVGART or VYVGART HYTRULO until the infection has resolved.</p>
2889<h4>Immunization</h4>
2890<p>Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of a new treatment cycle with VYVGART or VYVGART HYTRULO. The safety of immunization with live vaccines and the immune response to vaccination during treatment with VYVGART or VYVGART HYTRULO are unknown. Because VYVGART and VYVGART HYTRULO cause a reduction in immunoglobulin G (IgG) levels, vaccination with live vaccines is not recommended during treatment with VYVGART or VYVGART HYTRULO.</p>
2891<h4>Hypersensitivity Reactions</h4>
2892<p>In clinical trials, hypersensitivity reactions, including rash, angioedema, and dyspnea were observed in patients treated with VYVGART or VYVGART HYTRULO. Urticaria was also observed in patients treated with VYVGART HYTRULO. Hypersensitivity reactions were mild or moderate, occurred within 1 hour to 3 weeks of administration. Anaphylaxis and hypotension leading to syncope have been reported in postmarketing experience with intravenous efgartigimod alfa-fcab. Anaphylaxis and hypotension occurred during or within an hour of administration and led to infusion discontinuation and in some cases to permanent treatment discontinuation. Monitor for clinical signs and symptoms of hypersensitivity reactions during and for 1 hour after VYVGART administration, or for at least 30 minutes after VYVGART HYTRULO administration. If a hypersensitivity reaction occurs, the healthcare professional should institute appropriate measures if needed or the patient should seek medical attention.</p>
2893<h4>Infusion-Related Reactions</h4>
2894<p>Infusion-related reactions have been reported with VYVGART in postmarketing experience. The most frequent symptoms and signs were hypertension, chills, shivering, and thoracic, abdominal, and back pain. Infusion-related reactions occurred during or within an hour of administration and led to infusion discontinuation. If a severe infusion-related reaction occurs during administration, discontinue VYVGART infusion and initiate appropriate therapy. Consider the risks and benefits of readministering VYVGART following a severe infusion-related reaction. If a mild to moderate infusion-related reaction occurs, patients may be rechallenged with close clinical observation, slower infusion rates, and pre-medications.</p>
2895<h4>Infusion/Injection-Related Reactions</h4>
2896<p>Infusion-related reactions have been reported with intravenous efgartigimod alfa-fcab in postmarketing experience. The most frequent symptoms and signs were hypertension, chills, shivering, and thoracic, abdominal, and back pain. Infusion-related reactions occurred during or within an hour of administration and led to infusion discontinuation. If a severe infusion/injection-related reaction occurs, initiate appropriate therapy. Consider the risks and benefits of readministering VYVGART HYTRULO following a severe infusion/injection-related reaction. If a mild to moderate infusion/injection-related reaction occurs, patients may be rechallenged with close clinical observation, slower infusion/injection rates, and pre-medications.</p>
2897<h4>ADVERSE REACTIONS</h4>
2898<p>In Study 1, the most common (≥10%) adverse reactions in efgartigimod alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. In Study 2, the most common (≥10%) adverse reactions in VYVGART HYTRULO-treated patients were injection site reactions and headache. Injection site reactions occurred in 38% of VYVGART HYTRULO-treated patients, including injection site rash, erythema, pruritus, bruising, pain, and urticaria. In Study 2 and its open-label extension, all injection site reactions were mild to moderate in severity and did not lead to treatment discontinuation. The majority occurred within 24 hours after administration and resolved spontaneously. Most injection site reactions occurred during the first treatment cycle, and the incidence decreased with each subsequent cycle.</p>
2899<h4>USE IN SPECIFIC POPULATIONS<br />
2900Pregnancy</h4>
2901<p>As VYVGART and VYVGART HYTRULO are expected to reduce maternal IgG antibody levels, reduction in passive protection to the newborn is anticipated. Risk and benefits should be considered prior to administering live vaccines to infants exposed to VYVGART or VYVGART HYTRULO in utero.</p>
2902<h4>Lactation</h4>
2903<p>There is no information regarding the presence of efgartigimod alfa-fcab from administration of VYVGART, or efgartigimod alfa or hyaluronidase from administration of VYVGART HYTRULO, in human milk, the effects on the breastfed infant, or the effects on milk production. Maternal IgG is known to be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for VYVGART or VYVGART HYTRULO, and any potential adverse effects on the breastfed infant from VYVGART or VYVGART HYTRULO or from the underlying maternal 
2903condition.</p>
2904<h4>INDICATION</h4>
2905<p>VYVGART® (efgartigimod alfa-fcab) for intravenous infusion and VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous injection are each indicated for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.<br />
2906<br />
2907Please see the full <a href="https://argenx.com/content/dam/argenx-corp/products/vyvgart-prescribing-information.pdf">Prescribing Information</a> for VYVGART and the full <a href="https://argenx.com/content/dam/argenx-corp/products/vyvgart-hytrulo-prescribing-information.pdf">Prescribing Information</a> for VYVGART HYTRULO.</p>
2908<p>You may report side effects to the US Food and Drug Administration by visiting <a href="https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program">http://www.fda.gov/medwatch</a> or calling 1-800-FDA-1088. You may also report side effects to argenx US, Inc, at 1-833-argx411 (1-833-274-9411).</p>
2909<p><b>Dosage Forms and Strengths:</b> VYVGART Hytrulo is available as a single-dose subcutaneous injection containing 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial.</p>
2910<p>VYVGART is available as a single-dose injection for intravenous use containing 400 mg/20 mL of efgartigimod alfa-fcab per vial.</p>
2911
2912</div>
2913
2914    
2915
2916</div>
2917
2918        
2919    </div>
2920
2921</div>
2922
2923        
2924    </div>
2925
2926</div>
2927
2928    
2929</div>
2930
2931    </div>
2932
2933    
2934</div>
2935                <!-- Video Section start -->
2936                
2937                <!-- Video Section end -->
2938
2939                <!-- Content for the post video screen start -->
2940                
2941                <!-- Content for the post video screen end -->
2942            </div>
2943        </div>
2944    </div>
2945
2946
2947
2948    
2949</div>
2950<div class="overlay-modal">
2951     <!-- Load vimeo player API -->
2952    
2953    <div id="modal__contact-a-rep" class="cmp-overlay-modal-pre__main-wrapper" data-modal-animation="none" aria-modal="true" role="dialog" aria-hidden='true'>
2954        <div class="cmp-overlay-modal-pre__main-backdrop"></div>
2955        <div class="cmp-overlay-modal-pre__main-modal">
2956            <div class="cmp-overlay-modal-pre__main-modal-close-button" tabindex="0">
2957                <span></span>
2958                <span></span>
2959            </div>
2960            <div class="cmp-overlay-modal-pre__main-modal-content">
2961
2962                
2963
2964                
2965
2966                
2967                 <!-- Experience Fragment start -->
2968                <div id="overlay-modal-c423fb9e92" class="cmp-experiencefragment cmp-experiencefragment--contact-a-rep">
2969
2970
2971    
2972    <div id="container-40d8671bb5" class="cmp-container">
2973        
2974
2975
2976<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 ">
2977    
2978    <div class="container responsivegrid vyvgarthcp-container--modal __contact-a-rep-cidp __close aem-GridColumn aem-GridColumn--default--12">
2979
2980    
2981    <div id="container-8e2d797790" class="cmp-container">
2982        
2983
2984
2985<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 ">
2986    
2987    <div class="button aem-GridColumn aem-GridColumn--default--12">
2988<button type="button" id="modal-x" class="cmp-button" target="_self">
2989    
2990    <span class="cmp-button__icon cmp-button__icon--modal-x" aria-hidden="true"></span>
2991
2992     <!--Added context for the button text-->
2993</button>
2994</div>
2995<div class="contact-a-rep contact-a-rep-modal gmg-modal aem-GridColumn aem-GridColumn--default--12"><div class="contact-a-rep--gmg modal-overlay" id="gmg">
2996    <div class="modal">
2997        <form id="contact-rep-form" data-endpoint-url="/content/vyvgart/us/en/hcp/jcr:content.contact-a-rep.html" data-formtype="gmg">
2998            <div class="modal-wrapper">
2999                
3000                
3001                    
3002
3003
3004<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 ">
3005    
3006    <div class="container responsivegrid vyv-spacing--bottom-sm-7 aem-GridColumn aem-GridColumn--default--12">
3007
3008    
3009    
3010    
3011    <div id="container-9d0b8035f2" class="cmp-container">
3012        
3013        <div class="text vyvh-cidp-text--section-label perfectly-violet">
3014<div id="text-9ce923dd21" class="cmp-text">
3015    <p style="	text-align: center;
3016">For US healthcare professionals only</p>
3017
3018</div>
3019
3020    
3021
3022</div>
3023<div class="text vyvgarthcp-color--perfectly-violet vyv-spacing--top-sm-7">
3024<div id="text-06f7b734a2" class="cmp-text">
3025    <p style="	text-align: center;
3026"><b>If you are a patient, please <a href="https://www.vyvgart.com/">click here</a>
3026 or call the VYVGART gMG 
Education Line (inbound number: 1-833-VYVGART [1-833-898-4278])</b></p>
3027
3028</div>
3029
3030    
3031
3032</div>
3033<div class="separator">
3034<div id="separator-18e718535a" class="cmp-separator">
3035    <hr class="cmp-separator__horizontal-rule"/>
3036</div></div>
3037
3038        
3039    </div>
3040
3041</div>
3042<div class="text vyvgarthcp-color--perfectly-violet vyv-spacing--bottom-sm-4 aem-GridColumn aem-GridColumn--default--12">
3043<div id="text-37deb47f3a" class="cmp-text">
3044    <h6 style="	text-align: center;
3045"><b>CONTACT A REP</b></h6>
3046
3047</div>
3048
3049    
3050
3051</div>
3052<div class="text vyv-spacing--bottom-sm-10 aem-GridColumn aem-GridColumn--default--12">
3053<div id="text-e105141a06" class="cmp-text">
3054    <h2 style="	text-align: center;
3055">Our argenx representatives can give healthcare professionals and office staff more information about <b>treatment for gMG</b></h2>
3056
3057</div>
3058
3059    
3060
3061</div>
3062<div class="container responsivegrid vyv-spacing--bottom-sm-4 vyvgarthcp-spacing--mobile-bottom--none flex _fill flex-gap-xs _reset-mobile input-row three-input-row aem-GridColumn aem-GridColumn--default--12">
3063
3064    
3065    
3066    
3067    <div id="container-1b5dc050af" class="cmp-container">
3068        
3069        <div class="text">
3070  <div class="cmp-form-text" data-cmp-is="formText" data-cmp-constraint-message="all fields are required">
3071 
3072 
3073 
3074 <input class="cmp-form-text__text" data-cmp-hook-form-text="input" aria-label="First Name" type="text" id="first-name" placeholder="First name" name="firstName" required aria-describedby="first-name-helpMessage"/>
3075</div></div>
3076<div class="text">
3077  <div class="cmp-form-text" data-cmp-is="formText">
3078 
3079 
3080 
3081 <input class="cmp-form-text__text" data-cmp-hook-form-text="input" aria-label="Last Name" type="text" id="last-name" placeholder="Last name" name="lastName" required aria-describedby="last-name-helpMessage"/>
3082</div></div>
3083<div class="text">
3084  <div class="cmp-form-text" data-cmp-is="formText">
3085 
3086 
3087 
3088 <input class="cmp-form-text__text" data-cmp-hook-form-text="input" aria-label="ZIP Code" type="text" id="zip-code" placeholder="ZIP code" name="postalCode" required aria-describedby="zip-code-helpMessage"/>
3089</div></div>
3090
3091        
3092    </div>
3093
3094</div>
3095<div class="container responsivegrid vyv-spacing--bottom-sm-4 vyvgarthcp-spacing--mobile-bottom--none flex _fill flex-gap-xs _reset-mobile aem-GridColumn aem-GridColumn--default--12">
3096
3097    
3098    
3099    
3100    <div id="container-bdc5ed194f" class="cmp-container">
3101        
3102        <div class="text">
3103  <div class="cmp-form-text" data-cmp-is="formText">
3104 
3105 
3106 
3107 <input class="cmp-form-text__text" data-cmp-hook-form-text="input" aria-label="Email" type="text" id="email" placeholder="Email address" name="email" required aria-describedby="email-helpMessage"/>
3108</div></div>
3109<div class="text">
3110  <div class="cmp-form-text" data-cmp-is="formText">
3111 
3112 
3113 
3114 <input class="cmp-form-text__text" data-cmp-hook-form-text="input" aria-label="Phone Number" type="text" id="phoneNumber" placeholder="Phone number (optional)" name="mobilePhone" aria-describedby="phoneNumber-helpMessage"/>
3115</div></div>
3116
3117        
3118    </div>
3119
3120</div>
3121<div class="container responsivegrid vyv-spacing--bottom-sm-4 vyvgarthcp-spacing--mobile-bottom--none flex _fill flex-gap-xs _reset-mobile input-row aem-GridColumn aem-GridColumn--default--12">
3122
3123    
3124    
3125    
3126    <div id="container-1262bd596c" class="cmp-container">
3127        
3128        <div class="options _flex _reset-flex-mobile">
3129
3130
3131    <fieldset class="cmp-form-options cmp-form-options--drop-down" id="form-options-1856017657">
3132        
3133        
3134            <label class="cmp-form-options__label" for="form-options-1856017657"> What is your role in the treatment journey?</label>
3135            <select class="cmp-form-options__field cmp-form-options__field--drop-down" required="true" name="treatmentJourneyRole" id="form-options-1856017657">
3136                
3137                
3138                    <option value="...">Select...</option>
3139                
3140                    <option value="Neurologist">Neurologist</option>
3141                
3142                    <option value="Neuromuscular specialist">Neuromuscular specialist</option>
3143                
3144                    <option value="Neuro-ophthalmologist">Neuro-ophthalmologist</option>
3145                
3146                    <option value="Physician">Physician</option>
3147                
3148                    <option value="Physician assistant (PA)">Physician assistant (PA)</option>
3149                
3150                    <option value="Nurse practitioner (NP)">Nurse practitioner (NP)</option>
3151                
3152                    <option value="Nurse">Nurse</option>
3153                
3154                    <option value="Medical staff">Medical staff</option>
3155                
3156                    <option value="Office staff">Office staff</option>
3157                
3158                    <option value="Infusion center staff">Infusion center staff</option>
3159                
3160                    <option value="Resident / Fellow">Resident / Fellow</option>
3161                
3162                    <option value="Pharmacist">Pharmacist</option>
3163                
3164                    <option value="Other">Other</option>
3165                
3166            </select>
3167        
3168        
3169    </fieldset>
3170
3171
3172    
3173</div>
3174
3175        
3176    </div>
3177
3178</div>
3179<div class="container responsivegrid aem-GridColumn aem-GridColumn--default--12">
3180
3181    
3182    
3183    
3184    <div id="container-f76cb7b9c2" class="cmp-container">
3185        
3186        <div class="hidden field-optional">
3187<input type="hidden" id="privacy-policy" name="Privacy Policy.*" value="https://www.argenx.com/privacy-policy"/>
3188    
3189
3190</div>
3191
3192        
3193    </div>
3194
3195</div>
3196<div class="text vyvgarthcp-text--small vyv-spacing--bottom-sm-4 vyvgarthcp-text--p-margin-bottom-xs vyv-spacing--top-sm-4 modal__body--content aem-GridColumn aem-GridColumn--default--12">
3197<div id="text-e8b3f7860c" class="cmp-text">
3198    <p style="	text-align: center;
3199">I authorize argenx to contact me for marketing purposes, such as to provide me with information, offers and promotions regarding argenx therapeutic areas, products, and programs, to conduct market research or surveys, and to use my Information to develop future products, services and programs. I understand that I may withdraw my authorization provided above by emailing <a href="mailto:privacy&#64;argenx.com">privacy&#64;argenx.com</a> or following the unsubscribe instructions on the communication. Unless I withdraw this authorization, it will remain effective for 5 years. Copies of this authorization may be obtained by emailing <a href="mailto:privacy&#64;argenx.com">privacy&#64;argenx.com</a>.</p>
3200<p style="	text-align: center;
3201">By clicking “I Agree,” I agree to the terms and conditions shown above and certify that I am 18 years of age or older. I understand that argenx’s Privacy Policy can be found at this <a href="https://argenx.com/privacy-policy" target="_blank" rel="noopener noreferrer">link</a>.</p>
3202
3203</div>
3204
3205    
3206
3207</div>
3208<div class="button modal__body--btn _center aem-GridColumn aem-GridColumn--default--12">
3209<button type="BUTTON" id="submit-form" class="cmp-form-button" name="submit-form">I agree</button>
3210</div>
3211<div class="hidden aem-GridColumn aem-GridColumn--default--12">
3212<input type="hidden" id="form-hidden-1777517390" name="country" value="US"/>
3213    
3214
3215</div>
3216<div class="hidden aem-GridColumn aem-GridColumn--default--12">
3217<input type="hidden" id="form-hidden-1198810345" name="region" value="US"/>
3218    
3219
3220</div>
3221<div class="hidden aem-GridColumn aem-GridColumn--default--12">
3222<input type="hidden" id="form-hidden-1973383868" name="partitionName" value="US"/>
3223    
3224
3225</div>
3226
3227    
3228</div>
3229
3230                
3231                <input type="hidden" class="formType" name="formType" value="gmg"/>
3232                
3233    
3234
3235            </div>
3236            <button id="closeModal">
3237                <span class="modal__close--icon"></span>
3238            </button>
3239            <div class="modal__header thankyou-modal" id="thankyou-modal">
3240                <div class="modal__header--pretitle">
3241                    <h6>CONTACT A REP</h6>
3242                </div>
3243                <div class="modal__header--title">
3244                    <h3 id="thankyou">Thank You!</h3>
3245                </div>
3246                <div class="modal__header--content">
3247                    <p>An argenx representative will reach out to you soon, so keep an eye on your inbox!</p>
3248                </div>
3249            </div>
3250        </form>
3251    </div>
3252</div></div>
3253
3254    
3255</div>
3256
3257    </div>
3258
3259    
3260</div>
3261
3262    
3263</div>
3264
3265    </div>
3266
3267    
3268</div>
3269                <!-- Video Section start -->
3270                
3271                <!-- Video Section end -->
3272
3273                <!-- Content for the post video screen start -->
3274                
3275                <!-- Content for the post video screen end -->
3276            </div>
3277        </div>
3278    </div>
3279
3280
3281
3282    
3283</div>
3284<div class="overlay-modal">
3285     <!-- Load vimeo player API -->
3286    
3287    <div id="modal__gmg-now-approved-all-serotypes" class="cmp-overlay-modal-pre__main-wrapper" aria-modal="true" role="dialog" aria-hidden='true'>
3288        <div class="cmp-overlay-modal-pre__main-backdrop"></div>
3289        <div class="cmp-overlay-modal-pre__main-modal">
3290            <div class="cmp-overlay-modal-pre__main-modal-close-button" tabindex="0">
3291                <span></span>
3292                <span></span>
3293            </div>
3294            <div class="cmp-overlay-modal-pre__main-modal-content">
3295
3296                
3297
3298                
3299
3300                
3301                 <!-- Experience Fragment start -->
3302                <div id="overlay-modal-9493dd16af" class="cmp-experiencefragment cmp-experiencefragment--now-approved-all-serotypes-popup">
3303
3304
3305    
3306    <div id="container-024fa8308d" class="cmp-container">
3307        
3308
3309
3310<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 ">
3311    
3312    <div class="container responsivegrid vyvgarthcp-container--modal vyv-now-approved-all-serotypes__popup __close aem-GridColumn aem-GridColumn--default--12">
3313
3314    
3315    <div id="container-3a959d7ad8" class="cmp-container">
3316        
3317
3318
3319<div class="aem-Grid aem-Grid--12 aem-Grid--default--12 ">
3320    
3321    <div class="image aem-GridColumn aem-GridColumn--default--12">
3322<div data-cmp-is="image" data-cmp-lazythreshold="0" data-cmp-src="/content/experience-fragments/vyvgart/us/en/hcp/now-approved-all-serotypes-popup/master/_jcr_content/root/container_copy_copy_/image.coreimg.90{.width}.png/1778078671070/now-approved-all-serotypes-co-branded-logos.png" data-cmp-widths="768,1200,1440,1980" data-asset="/content/dam/vyvgart/hcp/now-approved-all-serotypes-co-branded-logos.png" data-title="VYVGART Hytrulo and VYVGART" id="now-approved-all-serotypes-logo" class="cmp-image" itemscope itemtype="http://schema.org/ImageObject">
3323    
3324        <noscript data-cmp-hook-image="noscript">
3325            
3326            <img src="/content/experience-fragments/vyvgart/us/en/hcp/now-approved-all-serotypes-popup/master/_jcr_content/root/container_copy_copy_/image.coreimg.png/1778078671070/now-approved-all-serotypes-co-branded-logos.png" class="cmp-image__image" itemprop="contentUrl" data-cmp-hook-image="image" alt="VYVGART Hytrulo and VYVGART"/>
3327            
3328        </noscript>
3329    
3330    
3331    
3332</div>
3333
3334    
3335
3336</div>
3337<div class="button aem-GridColumn aem-GridColumn--default--12">
3338<button type="button" id="modal-x" class="cmp-button" target="_self">
3339    
3340    <span class="cmp-button__icon cmp-button__icon--modal-x" aria-hidden="true"></span>
3341
3342     <!--Added context for the button text-->
3343</button>
3344</div>
3345<div class="container responsivegrid aem-GridColumn aem-GridColumn--default--12">
3346
3347    
3348    
3349    
3350    <div id="container-a01261b8c4" class="cmp-container">
3351        
3352        <div class="text vyv-spacing--top-sm-7 vyv-spacing--bottom-sm-7 vyvgarthcp-text--font-weight-sm">
3353<div id="text-d934e9c581" class="cmp-text">
3354    <p style="	text-align: left;
3355"><span class="vyv-now-approved-all-serotypes__pill">NOW APPROVED</span></p><h2 style="	text-align: left;
3356">for adults with gMG<br />across all serotypes<sup>1,2</sup>:</h2>
3357</div>
3358
3359    
3360
3361</div>
3362<div class="text vyv-spacing--bottom-sm-7">
3363<div id="text-9a56ed0bee" class="cmp-text">
3364    <ul><li>Anti–AChR-Ab positive</li><li>Anti–MuSK-Ab positive</li><li>Anti–LRP4-Ab positive</li><li>Triple seronegative</li></ul>
3365</div>
3366
3367    
3368
3369</div>
3370
3371        
3372    </div>
3373
3374</div>
3375<div class="container responsivegrid flex flex-gap-xs _justify-center aem-GridColumn aem-GridColumn--default--12">
3376
3377    
3378    
3379    
3380    <div id="container-f90c61987b" class="cmp-container">
3381        
3382        <div class="button vyvh-cidp-button--primary">
3383<a id="button-f41c505edd" class="cmp-button" href="#contact-a-rep" target="_self">
3384    
3385    
3386
3387    <span class="cmp-button__text">Contact a rep</span> <!--Added context for the button text-->
3388</a>
3389</div>
3390<div class="text gmg-button">
3391<div id="text-3373286987" class="cmp-text">
3392    <div class="cmp-submenu-header--utility-item __with-sub"><span class="vyv-now-approved-all-serotypes__pi-trigger showInMobileMenu"><span class="cmp-button__text">Prescribing Information<span class="cmp-submenu-header--utility-item-chevron"></span></span></span><div class="cmp-submenu-header--sub--utility"><a href="https://www.argenx.com/product/vyvgart-hytrulo-prescribing-information.pdf" target="_blank" class="cmp-submenu-header--subItem" rel="noopener noreferrer">VYVGART Hytrulo</a><a href="https://www.argenx.com/product/vyvgart-prescribing-information.pdf" target="_blank" class="cmp-submenu-header--subItem" rel="noopener noreferrer">VYVGART</a></div></div>
3393</div>
3394
3395    
3396
3397</div>
3398
3399        
3400    </div>
3401
3402</div>
3403<div class="ghost aem-GridColumn aem-GridColumn--default--12">
3404
3405</div>
3406<div class="ghost aem-GridColumn aem-GridColumn--default--12">
3407
3408</div>
3409<div class="ghost aem-GridColumn aem-GridColumn--default--12">
3410
3411</div>
3412<div class="text aem-GridColumn aem-GridColumn--default--12">
3413<div id="text-1f27b42745" class="cmp-text">
3414    <div class="vyv-now-approved-all-serotypes__footer-disclaimer"><p>Before prescribing VYVGART Hytrulo or VYVGART, please read the Important Safety Information below.</p><p>Triple seronegative&#61;anti-AChR, anti-MuSK, and anti-LRP4 antibodies negative.<sup>1</sup><br />AChR-Ab&#61;acetylcholine receptor antibody; gMG&#61;generalized myasthenia gravis; LRP4-Ab&#61;low-density lipoprotein receptor-related protein 4 antibody; MuSK-Ab&#61;muscle-specific tyrosine kinase antibody.</p></div>
3415</div>
3416
3417    
3418
3419</div>
3420
3421    
3422</div>
3423
3424    </div>
3425
3426    
3427</div>
3428
3429    
3430</div>
3431
3432    </div>
3433
3434    
3435</div>
3436                <!-- Video Section start -->
3437                
3438                <!-- Video Section end -->
3439
3440                <!-- Content for the post video screen start -->
3441                
3442                <!-- Content for the post video screen end -->
3443            </div>
3444        </div>
3445    </div>
3446
3447
3448
3449    
3450</div>
3451
3452        
3453    </div>
3454
3455</div>
3456
3457
3458    
3459    
3460    
3461<script src="/etc.clientlibs/argenx/clientlibs/clientlib-argenx-global.lc-7e233df48ef69484095be8032747e9ad-lc.min.js"></script>
vendor: 1 bytes, line 3461
3461
3462<script src="/etc.clientlibs/argenx/clientlibs/clientlib-vyvgarthcp.lc-28595755efc817346321881572c9750c-lc.min.js"></script>
3462
3463
3464
3465
3466    
3467
3468    
3469    
3470<script src="/etc.clientlibs/clientlibs/granite/jquery/granite/csrf.lc-652a558c3774088b61b0530c184710d1-lc.min.js"></script>
vendor: 1 bytes, line 3470
3470
3471<script src="/etc.clientlibs/core/wcm/components/commons/site/clientlibs/container.lc-0a6aff292f5cc42142779cde92054524-lc.min.js"></script>
vendor: 1 bytes, line 3471
3471
3472<script src="/etc.clientlibs/argenx/clientlibs/clientlib-base.lc-4b1c9a0268e3f6b9533f1026e0bb9c62-lc.min.js"></script>
3472
3473
3474
3475
3476
3477
3478
3479
3480
3481    
3482
3483    
3484
3485    
3486
3487
3488        
3488<script type="text/javascript">_satellite.pageBottom();</script>
3488
3489
3490
3491    
3492    
3493    
3494
3495    
3496
3497
3498</body>
3499</html>

Line numbers count LF bytes from the start of the resource, as the search results do. Vendor segments are library code the classifier recognised; they are stored but not indexed. Bytes are shown as Latin1 characters, one per byte.